

Remarks

In view of the foregoing amendments and the following remarks, Applicants respectfully request reconsideration of the pending claims. Claims 1, 2, 6, 7, 9, 10, 12, and 13 are pending in this application, and are the subject of the present examination. Claims 24 through 35 have been added.

Newly added claim 24 recites nucleic acids encoding polypeptides having one or more changes in amino acid sequence selected from the group consisting of substitution of an amino acid by a residue having similar physiochemical characteristics; inactivation of N-glycosylation sites; deletion or replacement of Cys residues that are not essential for biological activity; and inactivated KEX2 protease processing sites. Support for these claims is found in the specification, page 21 line 13, through page 22, line 24. Accordingly, Applicants respectfully submit that these claims are allowable.

Newly added claim 25 recites polynucleotides encoding splice variants. Support for this claim is found in the specification, page 20, lines 8 through 6, in Example 8, and in SEQ ID NOs:5, 6, and 7. Newly added claim 26 recites a polynucleotide encoding a polypeptide comprising amino acids 51 through 188 of SEQ ID NO:3 (i.e., a polypeptide lacking the prodomain). Support for this claim is found in the specification, page 18, lines 15 through 17, and page 20, lines 11 through 14.

In reviewing the figure sent in with the Response to Restriction Requirement, Applicants noted that there was an error in the correlation of the name of the polypeptide and the SEQ ID number; a corrected figure is enclosed herewith. Applicants further note that the region of identity between the four polypeptides spans amino acids 63 through 192 of SEQ ID NO:3.

Applicants respectfully requests that the Examiner reconsider the restriction requirement as it relates to SEQ ID NOs:8, 9, and 10. Applicants notes the Examiner's assertion in the present Office Action that nucleotide sequences encoding different proteins are structurally distinct compounds, and the implication that the polypeptides of SEQ ID NOs:3, 5, 6 and 7 are different proteins. However, TDZ.1, TDZ.2 and TDZ.3 are in fact splice variants of IL-1 zeta, as discussed in Example 8 of the present specification. The splice variant-encoding polynucleotides (i.e., SEQ ID NOs:8, 9 and 10) do not encode different proteins than does SEQ IDNO:1, but simply variants of IL-1 zeta that result from alternate splicing. At worst, the splice variants might be regarded as species within the genus of IL-1 zeta polypeptides.

Nevertheless, in an effort to be cooperative and speed allowance of the claims, Applicants have amended the claims to remove references to non-elected sequences, without prejudice. Applicants specifically reserve the right to reintroduce claims directed to these polynucleotides if the restriction requirement is withdrawn. Alternatively, if the restriction requirement is maintained, Applicants reserve the right to pursue claims to the non-elected SEQ ID NOs in a divisional application or applications.

Objections to the claims

Claims 1 through 2 are objected to as reciting non-elected SEQ ID NOs. As described above, Applicants have amended the claims, without prejudice, to remove reference to non-elected SEQ ID NOs; accordingly, Applicants request that the objection be withdrawn.

Claims 9 through 10 are objected to for allegedly being directed to non-statutory subject matter in reciting 'host cells, which are alleged to encompass cells expressing IL-1 zeta polypeptides as found in nature. Applicants note that those of ordinary skill in the art would not regard a 'host cell transformed or transfected with...' as encompassing cells expressing IL-1 zeta as found in nature. Nonetheless, in an effort to be cooperative and speed allowance of the claims, Applicants have amended the claims to refer to 'isolated' cells; accordingly, Applicants request that the objection be withdrawn.

Rejections under 35 U.S.C. § 112

Claims 1, 2, 6, 7, 9, 10, 12 and 13 stand rejected under 35 USC § 112, first paragraph, because the specification, while being enabling for an isolated polynucleotide comprising the sequence set forth in SEQ ID NO:1 encoding the polypeptide of SEQ ID NO:3, a vector comprising said polynucleotide, a host cell comprising said vector, and a method of producing the encoded polypeptide, allegedly does not enable an isolated polypeptide that hybridizes to the polynucleotide of SEQ ID NO:1 that binds to an IL-1R family member, or an isolated polynucleotide that encodes a polypeptide that is 80% identical to the polypeptide of SEQ ID NO:3. According to the Examiner, the specification does not enable a person skilled in the art to which it pertains to make or use the invention commensurate with the scope of the claims.

The Examiner further asserts that the specification does not provide the requisite examples or representative number of different sequences that would allow the skilled

artisan to produce the claimed polynucleotides. According to the Examiner, the issue here is the breadth of the claims in light of the predictability of the art as determined by the number of working examples. In support of the rejection, the Examiner cites *Ex parte Forman* (230 USPQ 546; BPAI 1986) and *In re Wands*, setting forth the factors to be considered in determining whether the amount of experimentation required for the practice of an invention is to be regarded as undue (858 F.2d 731, 737, 8 USPQ2d 1400, 1404, CAFC 1988). Applicants respectfully disagree with the basis of the rejection.

The first factor set forth in *In re Wands* is the amount of experimentation required. As discussed in both *In re Wands* and *Ex parte Forman*, a determination of what constitutes undue experimentation is not merely quantitative, since a considerable amount of experimentation is permissible if it is merely routine. The present specification provides a very extensive disclosure of variants of the presently claimed IL-1 zeta polynucleotides (see pages 16 through 26), and moreover provides an assay by which one of ordinary skill in the art can determine the activity of an IL-1 zeta polypeptide (see Example 7, at page 60). The techniques used to make variants are well known in the art. Thus, to make the described and claimed variants and test them for the ability to bind to cells expressing IL-1 zeta receptors is a matter of routine experimentation, of which a considerable amount is permissible.

With respect to the second factor set forth in *In re Wands*, the amount of direction or guidance presented, Applicants reiterate the extensive teaching of the specification as discussed above. Moreover, those of ordinary skill in the art to which the presently claimed invention pertains are aware of a large body of information with respect to IL-1 family members. In teaching the relationship of IL-1 zeta to other IL-1 family members, the specification provides additional guidance to one of ordinary skill in the art with respect to structure and function of this novel IL-1 family member (see, for example, the discussion of full-length versus mature proteins, and the presence of a prodomain versus a classic signal peptide at page 18, lines 7 through 21).

Applicants have also provided working examples, the third factor set forth in *In re Wands*. In addition to providing three examples of variants that hybridize to the polynucleotide of SEQ ID NO:1 (namely the splice variants of SEQ ID NOs:5, 6 and 7), Applicants have provided an example of binding to a cell expressing IL-1 zeta receptor (see Example 7). Applicants respectfully note that, in light of the restriction requirement that is being maintained in the present case, it would be burdensome for Applicants to

disclose additional examples of IL-1 zeta polypeptides which would also apparently be regarded as distinct species.

As to the nature of the invention (the fourth factor in *In re Wands*), while the present invention and those described in the patent application at issue in *Ex parte Forman* might be regarded as falling under the broad umbrella of biotechnology, Applicants note that Forman et al., in contrast to Applicants, relied on techniques that were not, at the time the application was filed, well known or straightforward. Forman et al. also were not able to provide a precise structure for their claimed invention, as it relied on mutants of a bacterium, *Salmonella typhi*. The present invention, while differing structurally from that of Wands et al. (in being a cytokine rather than an antibody), shares important factors set forth in *Wands*, which are regarded as providing a basis for enablement of numerous species within a particular genus of biotechnological invention, namely readily enabled starting materials and methods well known in the art (neither of which were taught by Forman et al.).

The fifth factor set forth in *In re Wands* is the state of the prior art, which Applicants submit was quite advanced at the time the present application was filed. As evidence of this, Applicants submit herewith as Exhibit 1 an article by Smith et al. (*J. Biol. Chem.* 275(2):1169; 2000), describing four new members of the IL-1 superfamily. On page 1170, under the subheading *Structure Modeling*, Smith et al. discuss the structure modeling of the IL-1 superfamily utilizing a sequence alignment based on that known in the art for the IL-1's and IL-18, and implementing several programs that were also known in the art to further analyze and compare the structural aspects of IL-1 superfamily members (see Exhibit 2 for publication dates and abstracts for these references; copies will be provided at the Examiner's request). In Figure 1, the sequence alignment of IL-1 epsilon (referred to in Smith et al. as FIL-1 ϵ or FIL-1 ϵ) is compared to other IL-1 superfamily members, which allows one of ordinary skill in the art to predict the beta strands of IL-1 epsilon. A similar analysis for the presently claimed IL-1 family member is within the purview of one of ordinary skill in the art. Moreover, as shown in Figure 3 of Smith et al., the amino acid sequence of IL-1 epsilon can be folded into a structure that superimposes well onto the crystal structure of IL-1 alpha and IL-1 beta, with minimal energy violations. Applicants respectfully submit that the amino acid sequence encoded by the presently claimed polynucleotides can also be subject to such structural analysis.

Additionally, there have been several studies mapping receptor-binding sites of IL-1 family members by site-directed mutagenesis, as discussed in Evans et al. (*J. Biol.*

Chem. 270(19):11477; 1995, enclosed herewith as Exhibit 3). Those of ordinary skill in the art could, by the application of routine experimentation, carry out similar studies, and verify the receptor binding sites for IL-1 zeta. Moreover, the crystal structure of IL-1 receptor complexed with IL-1 beta has been deduced (Vigers et al., *Nature* 386:190; 1997, Exhibit 4), as has the crystal structure of IL-1 receptor complexed with IL-1ra (Schreuder et al., *Nature* 386:194; 1997, Exhibit 5). Such studies, performed using methods that are known in the art, can be similarly applied to IL-1 zeta, allowing one of ordinary skill in the art to prepare a genus of IL-1 zeta polynucleotides that hybridize to that of SEQ ID NO:1 and encode an IL-1 zeta polypeptide that binds to a cell expressing IL-1 zeta receptor, as well as polynucleotides that encode polypeptides that are at least 95% identical to that of SEQ ID NO:3, and that bind to cells expressing IL-1 zeta receptors. Thus, Applicants respectfully submit that any characterization of IL-1 zeta that might be necessary for the practice of the claimed invention is within the purview of one of ordinary skill in the art.

As regards the level of ordinary skill in the art, the sixth factor enumerated in *In re Wands*, Applicants submit that, in the art of molecular biology, the level of skill of one regarded as being of ordinary skill is very high, and knowledge of a variety of sophisticated techniques and methods is presumed. Thus, one of ordinary skill in the art is well-versed in the techniques disclosed in the present specification, and with the types of characterization discussed in the Exhibits included herewith. Moreover, those of ordinary skill in the art are prepared to conduct experimentation to analyze, make and test IL-1 zeta variants, and regard such experimentation as routine, as demonstrated by the references submitted herewith.

The seventh factor articulated in *In re Wands* relates to the predictability of the art to which the invention pertains. The field of molecular biology has advanced greatly since the subject applications of *Ex parte Forman* and *In re Wands* were filed. Moreover, rather than being reliant on the potentially capricious nature of organisms (which may require a deposit for enablement purposes), the present invention is based on a precisely identified chemical structure, an IL-1 zeta polynucleotide. At the time the present application was filed, structure/function relationships, particularly as they relate to the IL-1 family of polypeptides, were becoming better understood. Thus, the teaching of the present specification in combination with that which was well known in the art allows one of ordinary skill in the art to make reasonable predictions as to effects of changes in the primary structure of an IL-1 zeta polypeptide on the function thereof.

Regarding the final factor set forth in *In re Wands*, the breadth of the claims, Applicants respectfully submit that to limit the claimed invention to the exact IL-1 zeta polynucleotide of SEQ ID NO:1 when it is well within the knowledge of those skilled in the art to use routine experimental techniques to make and test a genus of IL-1 zeta polypeptides would unfairly limit Applicants' claims. Since the specification, in combination with the knowledge of those skilled in the art, teaches how to make IL-1 zeta polynucleotides that hybridize to the polynucleotide of SEQ ID NO:1 and encode polypeptides that bind cells expressing IL-1 zeta receptors, and polynucleotides encoding polypeptides 95% identical to a native IL-1 zeta polypeptide (i.e., that encoded by the polynucleotide of SEQ ID NO:1) and that bind to cells that express IL-1 zeta receptors, the specification enables the subject claims. Any requirement that Applicants limit the claims to specific polynucleotides does not adequately protect Applicants in view of the scope of the invention and the disclosure, and the level of skill in the art.

Moreover, the PTO has made it clear that the teaching required to support claims encompassing a number of molecules which are further limited by reciting an operable activity, is satisfied if the disclosure teaches how to make a candidate molecule and how to test the candidate molecule for the activity. *Ex parte Mark* 12 USPQ2d 1904 (BPAI 1989).

Accordingly, one of ordinary skill in the art could, at the time the instant application was filed, use the disclosed sequence information together with techniques that were known in the art, to predict a structure for IL-1 zeta. Moreover, one of ordinary skill in the art could, at the time the application was filed, use the crystal structure of IL-1 complexed with receptor or antagonist to predict which residues are important for receptor binding. Furthermore, one of ordinary skill in the art could, at the time the application was filed, use the known mutational analysis of IL-1 to predict residues important for activity of IL-1 zeta. Applicants respectfully submit that this characterization would allow one of ordinary skill in the art to predict variants of IL-1 zeta that would be likely to retain activity. Additionally, Applicants have described an assay that can be used to evaluate IL-1 zeta activity; thus, to prepare and test these variants would be a matter of routine experimentation. Accordingly, the claims are enabled and Applicants request that the rejection be withdrawn.

Claims 1, 2, 6, 7, 9-10, 12 and 13 stand rejected under 35 USC § 112, first paragraph, as allegedly containing subject matter which was not described in the

specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The Examiner asserts that the structure of polynucleotide sequences capable of hybridizing to the polynucleotide of SEQ ID NO:1 are not defined, and further that the structure of a nucleotide sequence encoding a polypeptide sequences have 80% identity to a polypeptide encoded by SEQ ID NO:1 is also not defined. The Examiner recites *Fiers v. Revel* 25 USPQ2d 1601, 1606 (CAFC 1993) and *Amgen Inc. v. Chugai Pharmaceutical Co. Ltd.* 18 USPQ2d 1016 (CAFC 1991) in support of the proposition that the nucleic acid itself is required. The Examiner concludes that, in *University of California v. Eli Lilly and Co.* (43 USPQ2d 1398, CAFC 1997), the court held that a generic statement which defines a genus of nucleic acid only by their functional activity does not provide an adequate written description of the genus.

At the outset, Applicants respectfully submit that the claims are not directed to nucleic acids described solely by function. Claim 1 recites polynucleotides capable of hybridizing to the polynucleotide of SEQ ID NO:1; as amended, the conditions under which hybridization occurs are stringent. The only polynucleotides that will hybridize to that of SEQ ID NO:1 under such conditions are those that share sufficient structure (i.e., sequence) with the polynucleotide of SEQ ID NO:1. Moreover, those of ordinary skill in the art are aware that, due to degeneracy in the genetic code, numerous polynucleotides (referred to as degenerate sequences) can encode the polypeptide of SEQ ID NO:3. Polynucleotides encoding polypeptides at least 95% identical to that of SEQ ID NO:3 are structurally related to these degenerate sequences in that they cannot vary to a degree that the encoded polypeptides vary more than is claimed. Thus, both claims 1 and 2 include structural elements (hybridization or percent identity) as well as functional elements (i.e., encoding a polypeptide that binds a cell expressing IL-1 zeta receptor) to describe the claimed polynucleotides.

While a listing of all polynucleotides that satisfy the structural elements of the claims could be prepared by one of ordinary skill in the art given the disclosure of the instant specification, Applicants respectfully submit that such a listing is not the only, or even the best, way to disclose a genus of IL-1 zeta polynucleotides. Moreover, the Federal Circuit has rejected the proposition that polynucleotides (or polypeptides) must be described by sequence in a series of recent cases. In *Enzo Biochem v. Gen-Probe*, the Federal Circuit summarized its holding in *Lilly*, then stated that:

[I]t is not correct, however, that all functional descriptions of genetic material fail to meet the written description requirement. [T]he written description requirement can be met by “show[ing] that an invention is complete by disclosure of sufficiently detailed, relevant identifying characteristics ...i.e., complete or partial structure, other physical and/or chemical properties, *functional characteristics when coupled with a known or disclosed correlation between function and structure*, or some combination of such characteristics.”

Enzo, 63 USPQ2d at 1613 (quoting the Patent and Trademark Office [PTO] Guidelines on Written Description, 66 Fed. Reg. At 1106) (emphasis supplied by the Federal Circuit). Again quoting the Guidelines, the Federal Circuit noted that the PTO included hypothetical examples based on the facts of *Eli Lilly* in its Synopsis of Application of Written Description Guidelines, one in which the description requirement is not met (Example 17, at 61-64), and a contrasting example in which genus claims to nucleic acids based on their hybridization properties were determined to be adequately described if the nucleic acids hybridize under highly stringent conditions to known sequences because such conditions dictate that all species within the genus will be structurally similar (see Example 9, at 35-37).

In *Amgen Inc. v. Hoechst Marion Roussel Inc.*, 65 USPQ2d 1385 (CAFC 2003), the court stated that in *Enzo* “we clarified that *Eli Lilly* did not hold that all functional descriptions of genetic material necessarily fail as a matter of law to meet the written description requirement; rather, the requirement may be satisfied if in the knowledge of the art the disclosed function is sufficiently correlated to a particular, known structure.” *Amgen*, 65 USPQ2d at 1398.

Moreover, as discussed above in response to the Examiner’s rejection of the claims under 35 USC § 112, first paragraph, as not being enabled, one of ordinary skill in the art could, at the time the instant application was filed, use the disclosed sequence information together with techniques that were known in the art, to predict a structure for IL-1 zeta. Moreover, one of ordinary skill in the art could, at the time the application was filed, use the crystal structure of IL-1 complexed with receptor or antagonist to predict which residues are important for receptor binding. Furthermore, one of ordinary skill in the art could, at the time the application was filed, use the known mutational analysis of IL-1 to predict residues important for activity of IL-1 epsilon. Applicants respectfully submit that this characterization provides sufficient correlation of structure with function to satisfy requirements for written description. Accordingly, the subject matter Applicants regard as

their invention is described in such a way as to demonstrate possession of the genus of IL-1 zeta polynucleotides claimed, and Applicants request that the rejection be withdrawn.

Rejections under 35 U.S.C. § 102

Claims 1, 2, 6, 7, 9, 10, 12 and 13 stand rejected under 35 USC § 102(e) as being allegedly anticipated by Yang Pan (U.S Patent 6,117,654). According to the Examiner, Pan teaches an isolated nucleic acid that shares 68.3% identity to the polynucleotide of SEQ ID NO:1, a vector comprising such nucleic acid, a host cell comprising the vector and a method of producing the encoded polypeptide. Moreover, the Examiner asserts that the encoded polypeptide of Pan binds to an IL-1 family member. Applicants respectfully disagree that Pan anticipates the claimed invention.

Applicants have amended claim 1 to recite a polynucleotide that is capable of hybridizing to the polynucleotide of SEQ ID NO:1 under conditions of high stringency wherein the polypeptide encoded by the polynucleotide binds a cell expressing IL-1 zeta receptor. Applicants respectfully submit that the nucleic acid of Pan would not hybridize to the polynucleotide of SEQ ID NO:1 under highly stringent conditions. Accordingly, claim 1 is not anticipated by Pan.

Claim 2 has been amended to recite a polypeptide comprising SEQ ID NO:3; a polypeptide that is at least 95% identical to a polypeptide of SEQ ID NO:3 and that binds a cell expressing IL-1 zeta receptor; and a fragment of the aforementioned polypeptides, wherein the fragment binds a cell expressing IL-1 zeta receptor, and further wherein the fragment comprises amino acid 51 through 188 of SEQ ID NO:3. Accordingly, claim 2 is not anticipated by Pan.

Moreover, claims 1 and 2 have been amended to recite binding to cells expressing an IL-1 zeta receptor. Applicants note that Pan discloses that the polypeptide they refer to as Tango 77 may bind to the IL-1 receptor or to a novel receptor. Pan neither teaches nor discloses cells expressing IL-1 zeta receptors. Accordingly, neither claim 1 nor claim 2 is anticipated by Pan.

The remaining claims, being dependant on claims 1 and 2, incorporate the aforementioned amendments and are thus also not anticipated by Pan. Accordingly, Applicants request that the rejection be withdrawn.

CONCLUSIONS

Claims 1, 2, 6, 7, 9, 10, 12, 13, and 24 through 35 are now pending in the application and are believed to be in condition for allowance. If the examiner has any questions or concerns about the present claims, she is asked to contact the undersigned at the direct dial number given below, to facilitate prosecution and speed allowance of the claims.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Patricia Anne Perkins", written in a cursive style.

Patricia Anne Perkins
Agent for Applicants
Registration No. 34,693

Immunex Corporation
Law Department
51 University Street
Seattle, WA 98101
Telephone (206) 587-0430

!!AA_MULTIPLE_ALIGNMENT 1.0
PileUp of: @/tmp/GCGRMIServer/199.238.129.56-
1059057194245.pileup/pileup.list

Symbol comparison table: GenRunData:blosum62.cmp CompCheck: 1102

GapWeight: 8
GapLengthWeight: 2

stdout MSF: 218 Type: P July 24, 2003 07:33 Check: 9799 ..

Name: TDZ1 (SEQ ID NO:8) Len: 218 Check: 3840 Weight: 1.00
Name: TDZ2 (SEQ ID NO:9) Len: 218 Check: 7928 Weight: 1.00
Name: TDZ3 (SEQ ID NO:10) Len: 218 Check: 7461 Weight: 1.00
Name: IL1z (SEQ ID NO:3) Len: 218 Check: 570 Weight: 1.00

//

1 50
TDZ1 MSFVGENSGV KMGSEDWEKD EPQCCLEDPA VSPLEPGPSL PTMNFVHTSP
TDZ2 MSFVGENSGV KMGSEDWEKD EPQCCLE... ..GP
TDZ3 MSFVGENSGV KMGSEDWEKD EPQCCLE... ..
IL1z ~~~~~~ ~~~~~~ ~~~~~~MSGC DRRETETKGK NSFKKRLRGP

51 100
TDZ1 KVKNLNPCKF SIHDQDHKVL VLDSGNLIAV PDKNYIRPEI FFALASSLSS
TDZ2 KVKNLNPCKF SIHDQDHKVL VLDSGNLIAV PDKNYIRP
TDZ3
IL1z KVKNLNPCKF SIHDQDHKVL VLDSGNLIAV PDKNYIRP
** *****

101 150
TDZ1 ASAEKGSPII LGVSKGEFCL YCDKDKGQSH PSLQLKKEKL MKLAAQKESA
TDZ2
TDZ3
IL1z

151 200
TDZ1 RRPFIYFRAQ VGSWNMLESA AHPGWFICTS CNCNEPVGVT DKFENRKHIE
TDZ2
TDZ3
IL1z

201 218
TDZ1 FSFQPVCKAE MSPSEVSD
TDZ2
TDZ3
IL1z

Four New Members Expand the Interleukin-1 Superfamily*

(Received for publication, October 15, 1999)

Dirk E. Smith, Blair R. Renshaw, Randal R. Ketchem, Marek Kubin, Kirsten E. Garka,
and John E. Sims†

From Immunex Corp., Seattle, Washington 98101

We report here the cloning and characterization of four new members of the interleukin-1 (IL-1) family (FIL1δ, FIL1ε, FIL1ζ, and FIL1η, with FIL1 standing for "Family of IL-1"). The novel genes demonstrate significant sequence similarity to IL-1α, IL-1β, IL-1ra, and IL-18, and in addition maintain a conserved exon-intron arrangement that is shared with the previously known members of the family. Protein structure modeling also suggests that the *FIL1* genes are related to IL-1β and IL-1ra. The novel genes form a cluster with the IL-1s on the long arm of human chromosome 2.

The cytokine interleukin-1 (IL-1)¹ elicits a wide array of biological activities that initiate and promote the host response to injury or infection, including fever, sleep, loss of appetite, acute phase protein synthesis, chemokine production, adhesion molecule up-regulation, vasodilatation, the pro-coagulant state, increased hematopoiesis, and production and release of matrix metalloproteinases and growth factors (1). It does so by activating a set of transcription factors that includes NFκB and AP-1, which in turn promote production of effectors of the inflammatory response, such as the inducible forms of cyclooxygenase and nitric oxide synthase (2, 3). Interleukin 1 activity actually resides in each of two molecules, IL-1α and IL-1β, which act by binding to a common receptor composed of a ligand binding chain, the type I IL-1 receptor, and a required signaling component, the IL-1R accessory protein (AcP) (4–7). A third member of the family, the IL-1 receptor antagonist (IL-1ra), also binds to the type I IL-1 receptor but fails to bring about the subsequent interaction with AcP, thus not only not signaling itself but also, by blocking the receptor, preventing the action of the agonist IL-1s (8, 9). Additional regulation is provided by the type II, or decoy, IL-1 receptor, which binds and sequesters the agonist IL-1s (especially IL-1β) without inducing any signaling response of its own (10–13). The two agonist IL-1s (IL-1α and IL-1β) are synthesized as larger precursors which undergo proteolytic removal of their pro-domains to generate the mature cytokines (14). At least for IL-1β, this processing is coupled to secretion (15, 16). IL-1ra, in contrast, contains a signal peptide and is secreted by the more traditional route through the endoplasmic reticulum (9).

* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequences reported in this paper for *FIL1δ*, *FIL1ε*, *FIL1ζ*, and *FIL1η* have been deposited in GenBank™ with accession numbers AF201830, AF201831, AF201832, and AF201833.

† To whom correspondence should be addressed: Immunex Corp., 51 University St., Seattle, WA 98101. Tel.: 206-389-4005; Fax: 206-233-9733; E-mail: sims@immunex.com.

¹ The abbreviations used are: IL, interleukin; AcP, accessory protein; IL-1ra, interleukin 1 receptor antagonist; PCR, polymerase chain reaction; PDF, probability density function; LPS, lipopolysaccharide.

Recently, another cytokine, interleukin 18 (17, 18) was recognized to be related to the interleukin-1 family based on the similarity of its amino acid sequence and predicted tertiary structure (19). IL-18 induces the production of γ-interferon from T cells, especially in combination with IL-12, and stimulates the killing activity of cytotoxic T lymphocytes and NK cells by up-regulating Fas ligand (20). Like the agonist IL-1s, IL-18 contains a prodomain that is removed by the same protease, caspase-1, that processes IL-1β (21, 22). Consistent with its being related to the IL-1s, IL-18 binds a receptor which is homologous to the IL-1 receptor. The ligand-binding chain IL-1Rrp1 (or IL-18Rα) (23, 24) was cloned initially on the basis of its homology to the IL-1R (25). The signaling subunit (IL-18Rβ) was originally named AcPL (AcP-like) for its similarity to the IL-1R signaling subunit (26). The IL-18 receptor subunits are encoded in the same gene cluster on chromosome 2 as are the type I and II IL-1 receptors (25–27).

We have searched for novel members of the IL-1 family. We report here the sequences and some of the characteristics of four genes that appear to have descended from the same common ancestor as did IL-1α, IL-1β, IL-1ra, and IL-18. We propose that these novel molecules be designated *FIL1δ*, *-ε*, *-ζ*, and *-η*, with *FIL1* being an acronym for *Family of IL-1*.

EXPERIMENTAL PROCEDURES

Cloning of Novel Human IL-1 Family Members

The following details supplement the general descriptions given under "Results" for the cloning of the individual IL-1 family members.

FIL1δ—A 469-base pair single-stranded ³²P-labeled PCR product spanning the entire mouse *FIL1δ* coding region (found in GenBank™ W08205) was used to probe a human placenta cDNA library (in λUni-ZAP XR; Stratagene number 937225) (hybridization in 40% formamide at 42 °C; wash in 0.3 M NaCl at 55 °C). Several clones were isolated, all of which appeared to lack the full open reading frame by comparison with mouse *FIL1δ*. Vector-anchored PCR on DNA from the same library was used to isolate the remaining coding sequence.

FIL1ε—A human genomic library (Stratagene catalog number 946205; in λFixII) was screened using a ³²P-labeled single-strand DNA probe corresponding to the entire IL-1-like coding sequence present in GenBank™ EST AA030324 (hybridization in 45% formamide at 42 °C; wash in 0.3 M NaCl at 63 °C). The insert from one positive plaque was mapped to locate the hybridizing region, sequencing of which then revealed the 3'-most exon of the human *FIL1ε* gene. 5.3 kilobases of human genomic DNA to the 5' side of this exon was isolated using the CLONTECH Human GenomeWalker kit (catalog number K1803-1). Sequencing of this DNA allowed identification of the remaining coding exons. The structure of the gene was confirmed by isolation of a PCR product in which the predicted exons were indeed spliced, using as template first-strand cDNA from the cell lines HL60 and THP1, and from human thymic tissue. Interestingly, while the original genomic DNA sequence coded for glutamine at amino acid 12, cDNA clones from all three sources contain arginine at amino acid 12.

FIL1ζ—The *FIL1ζ* open reading frame was identified in a cDNA library made from the pancreatic tumor cell line HPT-4.

FIL1η—A human genomic DNA sequenced to identify the *FIL1η* 3' exon was obtained using the CLONTECH Human GenomeWalker kit (catalog number K1803-1).

TABLE I
PCR primer sequences used for analyzing expression of novel IL-1 family member mRNA

On some occasions, a second PCR reaction using nested primers was performed for FIL1δ and FIL1ε. Cycle numbers and annealing temperatures are also given.

Molecule	Primary or nested	Sense/anti	Sequence	No. cycles	Anneal °C
FIL1δ	Primary	Sense	GGGAGTCTACACCCTGTGGAGCTCAA	30	58
FIL1δ	Primary	Antisense	CTGCTGGAAGTAGAAGTCTGTGATGG		
FIL1δ	Nested	Sense	GGAGCTCAAGATGGTCTGAGTGGGGCGCT	30	58
FIL1δ	Nested	Antisense	GCATTCCAGCCACCATTCTCGGGAAGCT		
FIL1ε	Primary	Sense	GACACACCTCAGCAGGGGAGCATTCCAGG	40	60
FIL1ε	Primary	Antisense	AACAGCATAGTTAACCCAAAGTCAGTAG		
FIL1ζ	Primary	Sense	TGAGATCCTATGTGAGGCTGTGATAGG	40	60
FIL1ζ	Primary	Antisense	TGCTATGAGATTCCCAGAGTCCAGGACC		
FIL1η	Primary	Sense	ACATCATGAACCCACAACGGGAGGCAGCAC	35	60
FIL1η	Primary	Antisense	CTCTATCCTGGAACCCAGCCACCCACAGC		
FIL1η	Nested	Sense	CCAAATCCTATGCTATTCTGATTCTCGAC	35	58
FIL1η	Nested	Antisense	GGATTTATTCCACAGAATCTAAGTAGAAG		

Structure Modeling

Template sequences for structure modeling were extracted from the Protein Data Bank (28). A sequence alignment for the superfamily was generated based on that proposed by Bazan *et al.* (19) for the IL-1s and IL-18, which appeared valid by examination of both cysteine and real *versus* predicted sheet alignments. Preliminary analysis using the program Gene Fold (29) demonstrated that the experimentally determined structures for IL-1β (Protein Data Bank designations 1hib, 2ilb, 1iob, 1itb, and 21bi) and IL-1ra (Protein Data Bank designations 1ilr, 1ira, and 1ilrp) were valid templates for the new IL-1 family members FIL1δ, FIL1ε, and FIL1ζ. Although the sequence identity of the new IL-1-like cytokines is greater to IL-1ra, Gene Fold showed a stronger match to the structure of IL-1β. In addition, the various IL-1β structures appear better aligned structurally (as seen by superposition) than do the IL-1ra structures, so both templates were used for modeling. Modeler (30) was used to generate a family of 20 structures for each query sequence. All structures showed a well defined core β-trefoil, with higher variability in the outer loops; the per molecule probability density function (PDF) used by modeler varied from 1194 to 1984. The structure with the lowest overall PDF violation was visualized using a variable width ribbon based on the per residue PDF violation and showed that the highest violation was in the region of highest structural difference between IL-1ra and IL-1β. At this point the cysteine positions for the three models were revisited to ensure that no disulfide links were missed. A representative structure for each model was chosen by first ordering the models within a family by total PDF violation. After discarding structures with obvious problems, such as knots, the remaining members were then superimposed onto their mean. The structure with the lowest all atom root mean square deviation from the mean was chosen as the representative structure. Finally, the models were analyzed using Procheck (31) and it was shown that the structures are valid at 2.0-Å resolution with no major structural problems. The structure models for FIL1δ, FIL1ε, and FIL1ζ can be examined by contacting the authors.

Intron/Exon Mapping

Intron placement was determined by direct cloning or amplification of genomic DNA from the various novel IL-1 loci. Primers were designed so that the PCR products overlapped one another to ensure that small introns were not overlooked. The sequence of the PCR products from genomic DNA was compared with the cDNA sequence in order to determine the exon/intron junctions.

Chromosome Mapping

Chromosome mapping was performed using the Genebridge 4 radiation hybrid panel (32) (catalog number RH02.05 from Research Genetics) which consists of 93 human/hamster hybrid cell lines. Genomic DNA from the cell lines was amplified using PCR primers specific for the human version of each novel IL-1 family gene. Products were separated by agarose gel electrophoresis and visualized by ethidium bromide staining. Each hybrid was scored in the following manner: 0 was assigned if there was clearly no amplification; 1 was assigned where there clearly was amplification; a score of 2 was assigned where the data was ambiguous. Scores were then submitted to the Whitehead Institute/MIT for chromosomal assignment and placement relative to known framework markers on the radiation hybrid map. Scores for each gene are as follows: FIL1δ, 1000000100000000100012010010012-

0000110110000100000000010100001000112000000010001000010001-0100; FIL1ε, 1010000100001000100011011210011000011011010010-00001000101010021011110000001000010001100010100; FIL1ζ, 1010-0001000010001000120122100100000110110100100000100010101001-1021110000001000010001120010100; FIL1η, 1220002000100000100-000010010010001200011002010000000001010000010002200000010-00010001100010100. Scores used for concomitant map placement of IL-1α, IL-1β, and IL-1ra were obtained from the NCBI (IL-1α, X02851; IL-1β, D20737 and AA150507; IL-1ra, H50548, R49297, and T72887).

Expression Analysis

First-strand cDNAs present in CLONTECH (Palo Alto, CA) Human Multiple Tissue cDNA Panels I (catalog number K1421-1) and II (catalog number K1420-1) and the Human Immune Panel (catalog number K1426-1) were screened by PCR amplification using primers given in Table I. The primers were designed to span introns so that products arising from genomic DNA and cDNA could be distinguished. In some cases, nested primers were used in a second PCR reaction. The presence of an amplification product for each gene/tissue combination was determined by analysis on agarose gels stained with ethidium bromide.

Alternatively, individual cell types from human peripheral blood were isolated from multiple donors, and stimulations were performed as described (33, 34, 41). In brief, NK cells were incubated with IL-12 (R & D Biosystems; 1 ng/ml) for either 2 or 4 h. T cells were unstimulated or stimulated with anti-CD3 (OKT-3 antibody, immobilized on plastic at 5 μg/ml) or with the combination of anti-CD3 and anti-CD28 (the anti-CD28 antibody was CK248, used in soluble form as a 1:500 dilution of ascites fluid), for 4 h. Monocytes were unstimulated, or stimulated with LPS (Sigma, 1 μg/ml) for 2 or 3 h. B cells were unstimulated, or stimulated with a combination of 005% SAC + 500 ng/ml CD40L trimer (Immunex) + 5 ng/ml IL-4 (Immunex) for 3.5 or 4 h. Dendritic cells were stimulated with LPS as for monocytes for 2 or 4 h. After isolation of RNA and synthesis of first-strand cDNA, PCR amplifications and gel analysis were performed as described above.

Expression of Novel IL-1 Family Proteins for Receptor Binding

Novel IL-1 family members, as well as control IL-1β and IL-18 molecules, were generated by transfection of expression vector constructs into COS cells using DEAE-dextran (35). Expression vectors used were pDC409 (36) for FIL1ε and FIL1ζ, or pDC412, a close relative, for FIL1δ and FIL1η. The unmodified open reading frames were used for FIL1δ, ε, and η. For FIL1ζ, the sequence beginning with Lys²⁷ (KNLN...) was fused downstream of the human immunoglobulin κ light chain signal peptide. IL-1β, with an ATG codon added to the N terminus of the mature form (beginning with Ala¹¹⁷), was expressed in pDC409. Human IL-18 was expressed as the mature form fused to the IL-7 signal peptide in the expression vector pDC206 (37). For radiolabeling, 48 h after transfection cells were starved of cysteine and methionine for 60 min, then labeled with 70 μCi/ml of a [³⁵S]cysteine/methionine mixture (Amersham; >1000 Ci/mmol) for 4–6 h. It is perhaps of interest that FIL1δ, FIL1ε, and FIL1η appear to be secreted from the COS cells despite the absence of either signal peptide or prodomain. C-terminal FLAG-tagged FIL1δ and -ε were partially purified from the conditioned medium using the tags, and their N termini sequenced. The N-terminal amino acid of the secreted FIL1ε was methionine 1; it had been modified by N-terminal acetylation. The N-terminal amino acid of the secreted FIL1δ is valine 2. Thus, there does not appear to have been




FIG. 1. Alignment of amino acid sequences for human members of the IL-1 superfamily. The full-length predicted translation products are shown for FIL18, - ϵ , - ζ , and - η , whereas the mature peptides, without prodomains or signal peptide, are given for IL-1 α , IL-1 β , IL-1 α , and IL-18. The alignment is based on that presented by Bazan *et al.* (19) with slight modifications. Bars above and below the sequence indicate regions of experimentally determined (IL-1 β and IL-1 α) or proposed β -strand. The vertical lines within each sequence indicate intron positions. Some of these are taken from GenBank™ (IL-1 α , accession number X03833; IL-1 β , accession number X04500; IL-1 α , accession number X64532; IL-18, accession number E17138). The rest were determined for this paper. The sequences of FIL18, FIL1 ϵ , FIL1 ζ , and FIL1 η have been deposited in GenBank™ (accession numbers AF201830, AF201831, AF201832, and AF201833).

cleavage of an unrecognized signal peptide or prodomain in either molecule. There are a number of proteins which, when transfected into COS cells, do not later appear in the medium, so this is not a general phenomenon attributable to leaky cells. However, the intracellular version of IL-1 α (icIL-1 α , a kind gift of William Arend, University of Colorado) also appears in the medium following transfection of COS cells. The significance of these findings is currently unknown.

Receptor Binding Assays

The novel IL-1 family members, present as ^{35}S -labeled proteins in conditioned medium from transfected COS cells, were tested for binding to Fc fusion proteins of the IL-1 receptor superfamily members (see Footnote 2 for general methods)² IL-1R type I, IL-1R AcP, IL-1Rrp1, IL-1Rrp2, IL-1R AcPL, and T1/ST2 as follows: 0.5–1.0 ml of conditioned medium was pre-cleared for 2 h at 4 °C with 50 μl of protein G-Sepharose (Amersham Pharmacia Biotech; 50% solution in phosphate-buffered saline) containing 1% Triton X-100, 0.02% NaN_3 , and protease inhibitors (Roche Molecular Biochemicals catalog number 1 836 145). After a brief spin (3 min, 1000 rpm), the supernatant was transferred to a fresh tube and incubated overnight at 4 °C with 1 μg of receptor/Fc fusion protein plus another 50 μl of protein G-Sepharose. The mixture was centrifuged briefly, and the supernatant mixed with 0.5 ml of phosphate-buffered saline containing 5% glucose and protease inhibitors and spun again. The pellet was washed four times with 1 ml of a solution containing 0.4 M NaCl, 0.05% SDS, 1% Nonidet P-40, and protease inhibitors, and resuspended in 25 μl of 2 \times reducing sample buffer (Zaxis, catalog number 220-2110106). Samples were run on 4–20% Tris glycine gels (Novex) and autoradiographed.

RESULTS

The four previously known members of the IL-1 family (IL-1 α , IL-1 β , IL-1 α , and IL-18), while possessing a low overall fractional amino acid identity, share certain common amino acid sequence motifs, the most obvious of which can be summarized as $\text{F}(\text{X}_{10-12})\text{FXS}(\text{AVS})\text{XX}(\text{PE})\text{XX}(\text{FY})(\text{LI})(\text{CAS})(\text{TC})$ where X is any amino acid, and parentheses indicate that one of the included amino acids is present at that position. There are similarities in intron placement within the family as well. Relying on the sequence similarity, we searched public EST data bases and found sequences corresponding to three novel IL-1 family members, described below as FIL18, FIL1 ϵ , and FIL1 ζ . A fourth novel family member, described below as FIL1 η , was originally revealed in a published patent application. Examination of the sequence (called IL-18 by the inventors) in the patent application suggested that it was derived from an aberrantly spliced mRNA. We searched for and found

an alternative form of mRNA that contains the conserved family sequence motif in the extreme 3' exon. A brief description of the cloning and characteristics of each of the family members is given below. The sequences, and a comparison with the previously known IL-1 superfamily members, are given in Fig. 1.

FIL18

A search of GenBank™ revealed a murine EST, accession number W08205, that resembled the known IL-1s but was not identical to any. The IMAGE clone corresponding to the EST was sequenced and found to contain the entire open reading frame of an IL-1-like molecule. Unlike the known family members, this novel polypeptide (called FIL18) appeared to contain neither a signal peptide nor a prodomain at the N terminus. A human FIL18 cDNA was then isolated from a human placenta cDNA library, using mouse FIL18 as a probe. The human sequence predicted an open reading frame similar to that of mouse FIL18. Multiple FIL18 cDNA clones from both species were subsequently isolated, and all had the same predicted open reading frame, with no evidence for isoforms containing either signal peptide or prodomain. Interestingly, among the cDNA clones from both species were found several different 5'-untranslated region sequences (data not shown). These different 5' sequences appear to derive from separate exons, in that they can be found (separately) in genomic sequence upstream of the FIL18 coding region, and have potential splice donor sites at their 3' ends. Presumably the FIL18 gene is transcribed from at least two promoters.

FIL1 ϵ

A later search of GenBank™ revealed a murine EST, accession number AA030324, that resembled a second novel IL-1 family member. Sequencing of the IMAGE clone corresponding to the EST showed an open reading frame that appeared to encode the C-terminal portion of an IL-1 molecule, but which could not be extended in the 5' direction. The mouse sequence was used to probe a human genomic library, and a positive clone was identified and the insert sequenced. The sequence revealed a 212-base pair region with homology to the 3'-most exon of mouse FIL1 ϵ . There was a potential splice acceptor site at the 5' end of this region, and a stop codon at the 3' end of the 70-amino acid open reading frame. More human genomic DNA to the 5' side of this open reading frame was then isolated and sequenced, revealing three additional putative exons with sequence similarity to the mouse EST and to other IL-1 family members. On the assumption that the four putative exons were

² Born, T. L., Morrison, L. A., Esteban, D. J., VandenBos, T., Thebeau, L. G., Chen, N., Spriggs, M. K., Sims, J. E., and Buller, M. L. (2000) *J. Immunol.*, in press.

spliced to form a single coding region, PCR primers were designed and used successfully to amplify the predicted product from several different human RNA sources. As for FIL1 δ , the predicted FIL1 ϵ reading frame contains neither a signal peptide nor a prodomain.

FIL1 ζ

A third EST, accession number AI014548, was found in GenBank™ that appeared to encode an IL-1-like molecule. However, further sequencing revealed that the corresponding (human) IMAGE clone contained a stop codon upstream of the open reading frame but no initiating methionine. Screening of two other cDNA libraries resulted in isolation of a second, distinct aberrant clone, as well as a clone that contained an open reading frame that did begin with a methionine and that extended for 192 amino acids. This last clone was named FIL1 ζ . Sequence comparison with other family members suggests that FIL1 ζ has a prodomain of some 15–30 amino acids.

Analysis of genomic DNA demonstrated that an intron lies between the nucleotides encoding the 23rd and 24th amino acids of the 192 amino acid open reading frame form (see Figs. 1 and 4). The stop codon-containing sequences found in the aberrant cDNA clones lie within this intron, and appear to be incorporated into mRNA by cryptic splicing events. Since we had found three different cDNA isoforms for FIL1 ζ , only one of which appeared to contain a functional open reading frame, it was important to determine the relative levels of the different transcripts. This was done by designing PCR primers that would amplify and distinguish the three isoforms, and using them to examine expression in a panel of first-strand cDNAs. The (presumably functional) FIL1 ζ transcript was found in lymph node, thymus, bone marrow stroma, lung, testis, and placenta (Table II). We could not detect the form of mRNA represented by the EST in any tissue, whereas that represented by the other form of "aberrant" mRNA was present in bone marrow stroma (from which we had originally isolated it), lung, and placenta but not in the other tissues (not shown). The mRNA encoding that form appeared to be much less abundant than the functional FIL1 ζ mRNA.

FIL1 η

A cDNA clone containing part of the FIL1 η sequence was originally identified in an osteoclastoma library (38). The DNA sequence presented in this document appeared to encode the N-terminal half of an IL-1 like molecule, which then diverged in the C-terminal portion. Since the C-terminal regions of the different IL-1 family members contain the greatest sequence conservation, including the motif described above, and since the point of divergence lay exactly at the position of a conserved intron in the IL-1 family (see below), we searched for an alternative transcript that might encode a more typical member of the family.

PCR with first strand cDNA templates from various tissue sources, using primers lying entirely within the 5'-half of the osteoclastoma coding sequence (38), gave products from tonsil, bone marrow, heart, placenta, lung, testis, and colon. Only very faint bands were obtained, and only in tonsil and testis, when a 5' primer from the 5'-half and a 3' primer from the 3'-half of the osteoclastoma coding sequence were used, consistent with our interpretation. Human genomic DNA containing the 5'-half of the osteoclastoma sequence and extending further downstream was then isolated and sequenced. A putative exon was found 823 base pairs downstream of the point of divergence of the osteoclastoma sequence from other family members; this putative exon contained the expected sequence motifs for the C-terminal portion of an IL-1 family member, as well as a

TABLE II
Expression data for novel IL-1 family members

The table summarizes all available expression data on the novel IL-1 family members. "-" indicates that the mRNA was looked for but not found; a blank space indicates that the analysis was not done for that particular gene/RNA combination. Positive results were derived as follows: "a", by PCR analysis from a panel of first strand cDNAs (Clontech); "b", by cDNA library screening; "c", by the existence of an EST; "d", by PCR analysis of an individual RNA. "e" indicates that expression of the gene was increased by LPS. In the source column for tissues, "pool" was a mixture of fetal lung, testis, and B cell. In the source column for human cell lines, MoT and HUT102 are T-cell lines; Raji is a B cell line; THP-1 and U937 are macrophage lines; IMTLH is an unpublished bone marrow stromal cell line, derived at Immunex; HL60 is an early hematopoietic precursor line; HPT-4 is a pancreatic tumor line; T84 is a colon tumor line. For FIL1 δ in lung, (a) indicates that the PCR product lacks exon 2. The PCR products for FIL1 δ , FIL1 ϵ , and FIL1 η were especially strong from tonsil RNA, while that for FIL1 ζ was strong in placenta and testis.

Source	FIL1 δ	FIL1 ϵ	FIL1 ζ	FIL1 η
Human tissue				
Spleen	-	a	-	-
Lymph node	a	a	a	-
Thymus	a	a	a	-
Tonsil	a	a	-	a
Bone marrow	-	b	a,b	a
Fetal liver	-	-	-	-
Leukocyte	-	a	-	-
Heart	-	-	-	a
Brain	a	-	-	-
Placenta	a,b	-	a	a
Lung	(a)	-	a	a
Liver	-	-	-	-
Skeleton muscle	a	-	-	-
Kidney	-	-	-	-
Pancreas	-	-	-	-
Prostate	a	-	-	-
Testis	a	-	a	a
Ovary	-	-	-	-
Small intestine	-	-	-	-
Colon	-	-	-	a
Fetal brain	-	b	-	-
NK cells	b	-	-	-
Parathyroid tumor	c	-	-	-
Colon tumor	-	-	c	-
Pool	-	-	c	-
Human cell lines				
Mo-T	-	b	-	-
HUT-102	-	b	-	-
Raji	-	b	-	-
THP-1	-	d	d	-
U937	-	-	d,e	-
IMTLH	-	d	d	-
HL60	-	d	d	-
HPT-4	-	b	b	-
T84	-	b	-	-
Mouse tissue				
Spleen	d,e	d,e	-	-
Kidney	b	-	-	-
Placenta/yolk sac	d	c	-	-
Embryo	c	-	-	-
Stomach	c	c	-	-
Tongue	c	c	-	-
Skin	c	-	-	-
Mouse cell lines				
Macrophage (RAW)	d,e	b,d,e	-	-

potential splice acceptor site at its 5' end. PCR primers designed to amplify a hypothetical cDNA formed by splicing of the 5' portion of the osteoclastoma sequence with this 3' exon did indeed give a product from human tonsil first strand cDNA, which when sequenced contained the predicted 157-amino acid open reading frame. The open reading frame, and the gene encoding it, were named FIL1 η . Like FIL1 δ and FIL1 ϵ , FIL1 η does not contain an apparent signal peptide or prodomain.

TABLE III
Sequence identity

The numbers represent percent sequence identity between the indicated IL-1 superfamily members, as determined by using the program "gap" (Wisconsin Package Version 10.0, Genetics Computer Group (GCG)). For IL-1 α , IL-1 β , IL-18, and IL-1ra, the mature peptide (lacking signal sequence or prodomain) was used for the comparison. For FIL1 ζ , the mature form was assumed to start with Lys27, based on primary sequence alignment and analysis of predicted eight-dimensional structure, and this sequence was used.

	IL-1 α	IL-1 β	IL-1ra	IL-18	FIL1 δ	FIL1 ϵ	FIL1 ζ	FIL1 η
IL-1 α	...	24	20	21	20	23	21	26
IL-1 β		...	31	17	32	27	24	32
IL-1ra			...	22	50	30	29	30
IL-18				...	27	20	21	21
FIL1 δ					...	31	35	37
FIL1 ϵ						...	36	46
FIL1 ζ							...	44
FIL1 η								...




FIG. 2. Dendrogram illustrating the relationship between members of the IL-1 superfamily. The dendrogram was generated by the program Treeview (40) using the amino acid sequence alignment produced by the program Pileup (Wisconsin Package Version 10.0, Genetics Computer Group (GCG), Madison, WI).

A Gene Family

Sequence Comparison—The novel members of the IL-1 family are approximately as similar to one another in sequence as they are to the classical IL-1s; this level of identity is in turn similar to that shown by the classical IL-1s among themselves. Typically any given pair of family members shows 20–35% sequence identity (Table III). Those that stand out as being more similar to one another than average are FIL1 δ /IL-1ra, FIL1 ϵ /FIL1 η , and FIL1 ζ /FIL1 η . These relationships can also be seen in the dendrogram presented in Fig. 2, in which it appears that IL-1 α , IL-1 β , and IL-18 form one sequence subfamily; FIL1 ϵ , FIL1 ζ , and FIL1 η form a second subfamily, and IL-1ra and FIL1 δ form a third. The novel members can easily




FIG. 3. Structure models. Structural models of IL-1 β and FIL1 ϵ were generated as described under "Experimental Procedures." The figure shows views looking down the opening of the barrel in the β -trefoil structures, as well as views of the models rotated by 90° along the x axis. Yellow, β -strand; green, coil; blue, β -turn.

be placed onto the structure-based sequence alignment presented by Bazan *et al.* (19) (Fig. 1).

Three-dimensional Protein Structure Prediction—The structures of FIL1 δ , FIL1 ϵ , and FIL1 ζ have been modeled using as templates the experimentally determined structures of IL-1 β and IL-1ra. The novel IL-1 superfamily member amino acid sequences could with minimal energy violations be folded into structures which superimpose well onto the IL-1 β and IL-1ra crystal structures. In particular, the core 12-stranded, β -trefoil structure appears well conserved (see Fig. 3 for FIL1 ϵ). The major points of difference between the FIL1 δ , FIL1 ϵ , and FIL1 ζ models, and between them and the experimental structures, lie in the loops connecting the β strands, where IL-1 β and IL-1ra also differ most from each other.

Genomic Structure—The known genes of the IL-1 family display a conserved pattern of intron placement and intron/exon junctions, clearly indicating their derivation from a common ancestor. The novel IL-1 family members presented here demonstrate the same pattern. The most C-terminal intron in the coding region always falls between codons, and lies immediately after the predicted β -strand 7. By analogy to the structure of the IL-1 α and IL-1 β genes, we have called this intron 5, even though the rest of the family has only three introns within the coding sequence (except IL-18, which has four). Intron 4 (the intron N-terminal to intron 5) falls between the first and second nucleotides of the codon, and lies just N-terminal to β -strand 4. Intron 3 is more variable in placement. In IL-1 α , IL-1 β , IL-18, and probably in FIL1 ζ , it lies within the prodomain, not far upstream of the site of processing. In the other family members, it appears to lie not far downstream of the initiating methionine. It is also more variable in placement within the codon, falling after either the first (IL-1 α , IL-1 β , IL-18, FIL1 ϵ , FIL1 ζ , FIL1 η) or second (IL-1ra, FIL1 δ) nucleo-

tide of the codon.

Chromosomal Location—The novel IL-1 family members have been mapped using the radiation hybrid method. They cluster on human chromosome 2q, between the framework markers D2S121 and D2S110 (not shown). The *IL-1α/IL-1β/IL-1ra* cluster lies within this same interval. At the level of resolution seen with the Genebridge 4 panel, the novel and classical IL-1 genes appear to be interspersed.

Expression Pattern

We have analyzed the expression pattern of the novel IL-1 family members in several ways. Using a panel of first strand cDNAs derived from various tissues as templates for PCR, we find that the novel family members are all expressed in lymphoid organs, although the detailed pattern differs somewhat from cytokine to cytokine (Table II). RNA for each is also present in a small number of non-lymphoid tissues. Table II also summarizes expression data obtained from cDNA library screening, from searching EST data bases, and from PCR analysis of individual RNA samples. No easy generalization about expression patterns, either for the individual cytokines or for the family, is obvious.

Hematopoietic Subsets—We wanted to look specifically at expression of each of the novel IL-1 family members in individual cell types from peripheral blood. Cells were prepared from human blood and cultured for a short time in various conditions. RNA was made and analyzed by RT-PCR for the presence of *FIL1δ*, *-ε*, *-ζ*, and *-η* (Table IV). All family members were expressed in activated monocytes and B cells. In most cases, there was some expression present in these cells even without stimulation. *FIL1δ* was also expressed in activated dendritic

cells. The only one of the family members expressed by T cells was *FIL1ε*.

Receptor Binding—We asked whether any of the novel IL-1 family members could bind to the known members of the IL-1 receptor family. Conditioned medium from COS cells transfected with each of the different novel ligands and labeled with [³⁵S]Cys/Met, as well as from COS cells transfected with IL-18 as a positive control, were incubated with Fc fusions of the characterized IL-1R family members (IL-1R type I, IL-1R AcP, IL-1Rrp1, IL-1Rrp2, AcPL, and T1/ST2), followed by precipitation of the Fc proteins using protein G. The precipitates were electrophoresed on SDS gels, and autoradiographed to see whether any of the ligands were able to bind to any of the receptors. While IL-18 was seen consistently to bind to IL-1Rrp1, no other complexes were observable using this technique (data not shown).

DISCUSSION

We describe here the discovery of novel genes that double the size of the IL-1 superfamily. Assessment of the *FIL1δ*, *FIL1ε*, *FIL1ζ*, and *FIL1η* genes as paralogs of *IL-1α*, *IL-1β*, *IL-1ra*, and *IL-18* is based on several factors. First, sequence alignment (Fig. 1) reveals certain conserved amino acid motifs. Not only is there easily recognizable conservation of primary structure, but the amino acid sequences readily allow modeling into a predicted three-dimensional structure that is conserved with the known IL-1s (Fig. 3). In addition, intron placement is highly conserved in these new genes and is similar to that found in the "traditional" IL-1s as well as *IL-18* (Figs. 1, 4). This provides an independent measure of evolution from a common ancestor. Finally, consistent with evolution by gene duplication, the new IL-1 superfamily members are all clustered in the same region of human chromosome 2q that contains *IL-1α*, *IL-1β*, and *IL-1ra*. *IL-18* is the only superfamily member that does not map to this location.

The novel IL-1 family members are expressed in a variety of hematopoietic and non-hematopoietic cell types. It is not easy to formulate generalizations about expression patterns, except to say that *FIL1ε* appears to be the only one of these putative cytokines routinely expressed in T cells, and (not unexpectedly) all of the family members are expressed in activated monocytes and B cells. From the infrequency of ESTs corresponding to these genes in GenBank™, as well as the number of PCR cycles required to detect an amplification product in positive RNA sources, it would appear that they are all expressed at relatively low abundance. Nevertheless, *FIL1δ*, *FIL1ε*, and

TABLE IV

Expression of novel family members in hematopoietic cell subsets

Expression of IL-1 family members was determined by PCR analysis of RNA isolated from subsets of peripheral blood mononuclear cells, obtained as described under "Experimental Procedures."

Cell subset	<i>FIL1δ</i>	<i>FIL1ε</i>	<i>FIL1ζ</i>	<i>FIL1η</i>
NK cell + IL-12	ND ^a	ND	+	ND
T cell	—	+	—	—
Monocyte	++	+	ND	+
Monocyte + LPS	++	++	++	++
B cell	++	+	—	+
B cell stimulated	++	+	+	+
Dendritic cell + LPS	++	—	ND	ND

^a ND, not done.

FIG. 4. Intron positions. Intron positions were taken from GenBank™ (*IL-1α*, accession number X03833; *IL-1β*, accession number X04500; *IL-1ra*, accession number X64532; *IL-18*, accession number E17138) or were determined for this paper by sequencing of genomic DNA (either directly cloned, or PCR amplified) and comparison to the cDNA sequences. The "intron 3," "intron 4," "intron 5" designations are by analogy with *IL-1α* and *IL-1β*, and do not imply that there are five introns in each of the other genes. Intron sizes, where known, are indicated. Amino acid numbers are given below the lines, and refer to the primary translation product.

	"intron 3"		"intron 4"		"intron 5"
<i>IL-1α</i>	GAA G...1936nt...AA ATC Glu G.....lu Ile 106		GCA G...1382nt...TG AAA Ala V.....al Lys 163		CTG AAG ...2350nt... GAG ATG Leu Lys Glu Met 205 206
<i>IL-1β</i>	GAA G...547nt...AA CCT Glu G.....lu Pro 100		CAA G...1236nt...TG GTG Gln V.....al Val 155		CTG GAG ...721nt... AGT GUA Leu Glu Ser Val 199 200
<i>IL-1ra</i>	TTC AG...1831nt...A ATC Phe Ar.....g Ile 38		GAA G...1377nt...AA AAG Glu G.....lu Lys 68		CTG GAG ...1498nt... GCA GTT Leu Glu Ala Val 106 107
<i>FIL1δ</i>	TTC CG...1381nt...A ATG Phe Ar.....g Met 9		AAA G...1187nt...GT GAA Lys G.....ly Glu 38		CTA GAG ...201nt... CCA GTG Leu Glu Pro Val 81 82
<i>FIL1ε</i>	AAA G...92nt...CA TTG Lys A.....la Leu 3		CCA G...511nt...TC ACT Pro V.....al Thr 41		CTG AAG ...1093nt... GAA AAG Leu Lys Glu Lys 88 89
<i>FIL1ζ</i>	AGA G...1870nt...GT CCA Arg G.....ly Pro 22		CCA G...386nt...AG ATC Pro G.....lu Ile 62		CTG AAG ...787nt... AAG GAG Leu Lys Lys Glu 110 111
<i>FIL1η</i>	CAA C...541nt...GG GAG Gln A.....rg Glu 4		CCT G...2100nt...TC ACT Pro V.....al Thr 40		CTT AAG ...823nt... GAA AAA Leu Lys Glu Lys 87 88
<i>IL-18</i>	GAT G...3383nt...AA AAC Asp G.....lu Asn 30		AGA G...1334nt...AT AAT Arg A.....sp Asn 75		TTT AAG ...4773nt... GAA ATG Pro Lys Glu Met 120 121

FIL1 ζ can be regulated by LPS (and most likely other agents) in monocytes and spleen cells, and FIL1 δ appears to be transcribed from at least two different promoters, indicating that regulation of expression in this family is active.

It might be expected that the new IL-1 superfamily members would bind to members of the IL-1 receptor superfamily. However, we have been unable to demonstrate this in co-precipitation assays using Fc fusions of the known receptors and orphan receptor homologs. It could be that there are as yet undiscovered members of the IL-1R superfamily. Alternatively, unlike the case with the IL-1s and IL-18, high affinity binding detectable by co-precipitation may require two receptor subunits to be present. Finally, of course, it is possible that these cytokines bind to a different type of receptor. IL-18, for example, was recently shown to be capable of binding with high affinity to a soluble protein that has little similarity to other IL-1R family members (39).

The biological activity of the novel IL-1 family members remains to be characterized. IL-1 α , IL-1 β , and IL-18 are all capable of activating gene expression programs that enhance immune responses and promote inflammation. It is obvious to speculate that FIL1 δ , FIL1 ϵ , FIL1 ζ , and FIL1 η might have similar actions. On the other hand, IL-1ra acts to block the actions of the agonist IL-1s, and it is possible that one or more of the novel family members might similarly play an antagonist role. In this context, however, it should be noted that none of them binds to either the type I IL-1R or to IL-1Rrp1, and therefore they presumably do not regulate signaling by either IL-1 or IL-18. It is also possible that the resemblance of these molecules to IL-1 says nothing at all about their receptor binding or the type of biological responses they might invoke. These issues will be clarified by further investigation.

Acknowledgments—We thank Tim Bonnert and Lisa Thomassen for early work on the ligands described in this paper; Teresa Born for reagents and helpful discussions; Janis Henry and Michael Kirschner for patent searches; Bob DuBose for help with dendrograms and sequence alignments; Ray Paxton, Rich Johnson, and Alison Wallace for help with FIL1 ϵ protein structure studies; Brian MacDuff and Linda Cassiano for provision of various hematopoietic cells; and William Arend for the icIL-1ra cDNA clone.

REFERENCES

- Dinareello, C. A. (1998) *Int. Rev. Immunol.* 16, 457–499
- O'Neill, L. A., and Greene, C. (1998) *J. Leukocyte Biol.* 63, 650–657
- Dinareello, C. A. (1996) *Blood* 87, 2095–2147
- Sims, J. E., March, C. J., Cosman, D., Widmer, M. B., MacDonald, H. R., McMahan, C. J., Grubin, C. E., Wignall, J. M., Call, S. M., Friend, D., Alpert, A. R., Gillis, S. R., Urdal, D. L., and Dower, S. K. (1988) *Science* 241, 585–589
- Sims, J. E., Acres, R. B., Grubin, C. E., McMahan, C. J., Wignall, J. M., March, C. J., and Dower, S. K. (1989) *Proc. Natl. Acad. Sci. U. S. A.* 86, 8946–8950
- Greenfeder, S. A., Nunes, P., Kwee, L., Labow, M., Chizzonite, R. A., and Ju, G. (1995) *J. Biol. Chem.* 270, 13757–13765
- Cullinan, E. B., Kwee, L., Nunes, P., Shuster, D. J., Ju, G., McIntyre, K. W., Chizzonite, R. A., and Labow, M. A. (1998) *J. Immunol.* 161, 5614–5620
- Hannum, C. H., Wilcox, C. J., Arend, W. P., Joslin, F. G., Dripps, D. J., Heimdal, P. L., Armes, L. G., Sommer, A., Eisenberg, S. P., and Thompson, R. C. (1990) *Nature* 343, 336–340
- Eisenberg, S. P., Evans, R. J., Arend, W. P., Verderber, E., Brewer, M. T., Hannum, C. H., and Thompson, R. C. (1990) *Nature* 343, 341–346
- McMahan, C. J., Slack, J. L., Mosley, B., Cosman, D., Lupton, S. D., Brunton, L. L., Grubin, C. E., Wignall, J. M., Jenkins, N. A., Brannan, C. J., Copeland, N. G., Huebner, K., Croce, C. M., Cannizzaro, L. A., Benjamin, D., Dower, S. K., Spriggs, M. K., and Sims, J. E. (1991) *EMBO J.* 10, 2821–2832
- Colotta, F., Re, F., Muzio, M., Bertini, R., Polentarutti, N., Sironi, M., Giri, J. G., Dower, S. K., Sims, J. E., and Mantovani, A. (1993) *Science* 261, 472–475
- Colotta, F., Dower, S. K., Sims, J. E., and Mantovani, A. (1994) *Immunol. Today* 15, 562–566
- Sims, J. E., Gayle, M. A., Slack, J. L., Alderson, M. R., Bird, T. A., Giri, J. G., Colotta, F., Re, F., Mantovani, A., Shanebeck, K., Grabstein, K. H., and Dower, S. K. (1993) *Proc. Natl. Acad. Sci. U. S. A.* 90, 6155–6159
- March, C. J., Mosley, B., Larsen, A., Cerretti, D. P., Braedt, G., Price, V., Gillis, S., Henney, C. S., Kronheim, S. R., Grabstein, K., Conlon, P. J., Hopp, T. P., and Cosman, D. (1985) *Nature* 315, 641–647
- Cerretti, D. P., Kozlosky, C. J., Mosley, B., Nelson, N., Van Ness, K., Greenstreet, T. A., March, C. J., Kronheim, S. R., Druck, T., Cannizzaro, L. A., Huebner, K., and Black, R. A. (1992) *Science* 256, 97–100
- Thornberry, N. A., Bull, H. G., Calaycay, J. R., Chapman, K. T., Howard, A. D., Kostura, M. J., Miller, D. K., Molineaux, S. M., Weidner, J. R., Aunins, J., Elliston, K. O., Ayala, J. M., Casano, F. J., Chin, J., Ding, G. J.-F., Egger, L. A., Gaffney, E. P., Limjuco, G., Palyha, O. C., Raju, S. M., Rolando, A. M., Salley, J. P., Yamin, T.-T., Lee, T. D., Shively, J. E., MacCross, M., Mumford, R. A., Schmidt, J. A., and Tocci, M. J. (1992) *Nature* 356, 768–774
- Okamura, H., Tsutsi, H., Komatsu, T., Yutsudo, M., Hakura, A., Tanimoto, T., Torigoe, K., Okura, T., Nukada, Y., Hattori, K., Akita, K., Namba, M., Tanabe, F., Konishi, K., Fukuda, S., and Kurimoto, M. (1995) *Nature* 378, 88–91
- Ushio, S., Namba, M., Okura, T., Hattori, K., Nukada, Y., Akita, K., Tanabe, F., Konishi, K., Micallef, M., Fujii, M., Torigoe, K., Tanimoto, T., Fukuda, S., Ikeda, M., Okamura, H., and Kurimoto, M. (1996) *J. Immunol.* 156, 4274–4279
- Bazan, J. F., Timans, J. C., and Kastelein, R. A. (1996) *Nature* 379, 591
- Dinareello, C. A., Novick, D., Puren, A. J., Fantuzzi, G., Shapiro, L., Muhl, H., Yoon, D. Y., Reznikov, L. L., Kim, S. H., and Rubinstein, M. (1998) *J. Leukocyte Biol.* 63, 658–664
- Ghayur, T., Banerjee, S., Hugunin, M., Butler, D., Herzog, L., Carter, A., Quintal, L., Sekut, L., Talanian, R., Paskind, M., Wong, W., Kamen, R., Tracey, D., and Allen, H. (1997) *Nature* 386, 619–623
- Gu, Y., Kuida, K., Tsutsui, H., Ku, G., Hsiao, K., Fleming, M. A., Hayashi, N., Higashino, K., Okamura, H., Nakanishi, K., Kurimoto, M., Tanimoto, T., Flavell, R. A., Sato, V., Harding, M. W., Livingston, D. J., and Su, M. S.-S. (1997) *Science* 275, 206–209
- Torigoe, K., Ushio, S., Okura, T., Kobayashi, S., Taniai, M., Kunikata, T., Murakami, T., Sanou, O., Kojima, H., Fujii, M., Ohta, T., Ikeda, M., Ikegami, H., and Kurimoto, M. (1997) *J. Biol. Chem.* 272, 25737–25742
- Thomassen, E., Bird, T. A., Renshaw, B. R., Kennedy, M. K., and Sims, J. E. (1998) *J. Interferon Cytokine Res.* 18, 1077–1088
- Parnet, P., Garka, K. E., Bonnert, T. P., Dower, S. K., and Sims, J. E. (1996) *J. Biol. Chem.* 271, 3967–3970
- Born, T. L., Thomassen, E., Bird, T. A., and Sims, J. E. (1998) *J. Biol. Chem.* 273, 29445–29450
- Sims, J. E., Painter, S. L., and Gow, I. R. (1995) *Cytokine* 7, 483–490
- Bernstein, F. C., Koetzle, T. F., Williams, G. J., Meyer, E. F., Jr., Brice, M. D., Rodgers, J. R., Kennard, O., Shimanouchi, T., and Tasumi, M. (1977) *Eur. J. Biochem.* 80, 319–324
- Jaroszewski, L., Rychlewski, L., Zhang, B., and Godzik, A. (1998) *Protein Sci.* 7, 1431–1440
- Sali, A., Potterton, L., Yuan, F., van Vlijmen, H., and Karplus, M. (1995) *Proteins* 23, 318–326
- Laskowski, R. A., Rullmann, J. A., MacArthur, M. W., Kaptein, R., and Thornton, J. M. (1996) *J. Biomol. NMR* 8, 477–486
- Gyapay, G., Schmitt, K., Fizames, C., Jones, H., Vega-Czarny, N., Spillet, D., Muselet, D., Prud'Homme, J. F., Dib, C., Auffray, C., Morissette, J., Weissenbach, J., and Goodfellow, P. N. (1996) *Hum. Mol. Genet.* 5, 339–346
- Kubin, M., Kamoun, M., and Trinchieri, G. (1994) *J. Exp. Med.* 180, 211–222
- Kubin, M., Chow, J. M., and Trinchieri, G. (1994) *Blood* 83, 1847–1855
- Cosman, D., Cerretti, D. P., Larsen, A., Park, L., March, C., Dower, S., Gillis, S., and Urdal, D. (1984) *Nature* 312, 768–771
- Giri, J. G., Ahdieh, M., Eisenman, J., Shanebeck, K., Grabstein, K., Kumaki, S., Namen, A., Park, L. S., Cosman, D., and Anderson, D. (1994) *EMBO J.* 13, 2822–2830
- Kozlosky, C. J., Maraskovsky, E., McGrew, J. T., VandenBos, T., Teepe, M., Lyman, S. D., Srinivasan, S., Fletcher, F. A., Gayle, R. B., III, Cerretti, D. P., and Beckmann, M. P. (1995) *Oncogene* 10, 299–306
- Young, P. R., James, I. E., Connor, J. R. (November 25, 1998) European Patent Office publication EP 0 879 889 A2
- Novick, D., Kim, S. H., Fantuzzi, G., Reznikov, L. L., Dinareello, C. A., and Rubinstein, M. (1999) *Immunity* 10, 127–136
- Page, R. D. (1996) *Comput. Appl. Biosci.* 12, 357–358
- Kubin, M. Z., Parshley, D. L., Din, W., Waugh, J. Y., Davis-Smith, T., Smith, C. A., Macduff, B. M., Armitage, R. J., Chin, W., Cassiano, L., Borges, L., Petersen, M., Trinchieri, G., and Goodwin, R. G. (1999) *Eur. J. Immunol.* 29, 3466–3477

EXHIBIT 2

Smith et al. reference 19:

Nature 1996 Feb 15;379(6566):591

Comment on: *Nature* 1995 Nov 2;378(6552):88-91

A newly defined interleukin-1?

Bazan JF, Timans JC, Kastelein RA

Smith et al. reference 29:

Protein Sci 1998 Jun;7(6):1431-40

Fold prediction by a hierarchy of sequence, threading, and modeling methods.

Jaroszewski L, Rychlewski L, Zhang B, Godzik A.

Department of Chemistry, University of Warsaw, Warszawa, Poland.

Several fold recognition algorithms are compared to each other in terms of prediction accuracy and significance. It is shown that on standard benchmarks, hybrid methods, which combine scoring based on sequence-sequence and sequence-structure matching, surpass both sequence and threading methods in the number of accurate predictions. However, the sequence similarity contributes most to the prediction accuracy. This strongly argues that most examples of apparently nonhomologous proteins with similar folds are actually related by evolution. While disappointing from the perspective of the fundamental understanding of protein folding, this adds a new significance to fold recognition methods as a possible first step in function prediction. Despite hybrid methods being more accurate at fold prediction than either the sequence or threading methods, each of the methods is correct in some cases where others have failed. This partly reflects a different perspective on sequence/structure relationship embedded in various methods. To combine predictions from different methods, estimates of significance of predictions are made for all methods. With the help of such estimates, it is possible to develop a "jury" method, which has accuracy higher than any of the single methods. Finally, building full three-dimensional models for all top predictions helps to eliminate possible false positives where alignments, which are optimal in the one-dimensional sequences, lead to unsolvable sterical conflicts for the full three-dimensional models.

Smith et al. reference 30:

J Biomol NMR 1996 Dec;8(4):477-86

AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR.

Laskowski RA, Rullmannn JA, MacArthur MW, Kaptein R, Thornton JM.

Department of Biochemistry and Molecular Biology, University College London, UK.
roman@bsm.bioc.ucl.ac.uk

The AQUA and PROCHECK-NMR programs provide a means of validating the geometry and restraint violations of an ensemble of protein structures solved by solution NMR. The outputs include a detailed breakdown of the restraint violations, a number of plots in PostScript format and summary statistics. These various analyses indicate both the degree of agreement of the model structures with the experimental data, and the quality of their geometrical properties. They are intended to be of use both to support ongoing NMR structure determination and in the validation of the final results.

Smith et al. reference 31:

Proteins 1995 Nov;23(3):318-26

Evaluation of comparative protein modeling by MODELLER.

Sali A, Potterton L, Yuan F, van Vlijmen H, Karplus M.

Rockefeller University, New York, NY 10021, USA.

We evaluate 3D models of human nucleoside diphosphate kinase, mouse cellular retinoic acid binding protein I, and human eosinophil neurotoxin that were calculated by MODELLER, a program for comparative protein modeling by satisfaction of spatial restraints. The models have good stereochemistry and are at least as similar to the crystallographic structures as the closest template structures. The largest errors occur in the regions that were not aligned correctly or where the template structures are not similar to the correct structure. These regions correspond predominantly to exposed loops, insertions of any length, and non-conserved side chains. When a template structure with more than 40% sequence identity to the target protein is available, the model is likely to have about 90% of the mainchain atoms modeled with an rms deviation from the X-ray structure of approximately 1 Å, in large part because the templates are likely to be that similar to the X-ray structure of the target. This rms deviation is comparable to the overall differences between refined NMR and X-ray crystallography structures of the same protein.

EXHIBIT 3

THE JOURNAL OF BIOLOGICAL CHEMISTRY
© 1996 by The American Society for Biochemistry and Molecular Biology, Inc.

Vol. 270, No. 19, Issue of May 12, pp. 11477–11483, 1995
Printed in U.S.A.

Mapping Receptor Binding Sites in Interleukin (IL)-1 Receptor Antagonist and IL-1 β by Site-directed Mutagenesis

IDENTIFICATION OF A SINGLE SITE IN IL-1ra AND TWO SITES IN IL-1 β *

(Received for publication, September 7, 1994, and in revised form, December 20, 1994)

Ron J. Evans†, Jeff Bray§, John D. Childs¶, Guy P. A. Vigers, Barbara J. Brandhuber, Jack J. Skalicky¶**, Robert C. Thompson, and Stephen P. Eisenberg

From Synergen, Inc., Boulder, Colorado 80301 and the ¶Department of Chemistry and Biochemistry, University of Colorado, Boulder, Colorado 80309

Interleukin-1 receptor antagonist (IL-1ra), an IL-1 family member, binds with high affinity to the type 1 IL-1 receptor (IL-1RI), blocking IL-1 binding but not inducing an IL-1-like response. Extensive site-directed mutagenesis has been used to identify residues in IL-1ra and IL-1 β involved in binding to IL-1RI. These analyses have revealed the presence of two discrete receptor binding sites on IL-1 β . Only one of these sites is present on IL-1ra, consisting of residues Trp-16, Gln-20, Tyr-34, Gln-36, and Tyr-147. Interestingly, the absent second site is at the location of the major structural difference between IL-1ra and IL-1 β , which are otherwise structurally similar. The two receptor binding sites on IL-1 β are also present on IL-1 α . Thus, it appears that the two IL-1 agonist molecules have two sites for IL-1RI binding, and the homologous antagonist molecule, IL-1ra, has only one. Based on these observations, a hypothesis is presented to account for the difference in activity between the agonist and antagonist proteins. It is proposed that the presence of the two receptor binding sites may be necessary for agonist activity.

The IL-1¹ family of proteins are related by sequence similarity, gene organization, and three-dimensional structure (Eisenberg *et al.*, 1990, 1991; Carter *et al.*, 1990). The three proteins, IL-1 α , IL-1 β , and IL-1ra, all exhibit a β -trefoil topology characterized by six β -strands forming a tapered β -barrel, which is closed at the wide end by another six β -strands (Murzin *et al.*, 1992; Vigers *et al.*, 1994).

The two agonist proteins, IL-1 α and IL-1 β , have similar biological activities, mediated through their high affinity interaction with the type 1 IL-1 receptor (IL-1RI) (Sims *et al.*, 1993). These two proteins are believed to play an important role in causing both local and systemic inflammatory responses (Dinarello, 1991).

The third family member, IL-1ra, also binds with high affinity to IL-1RI but does not elicit a biological response (Hannum *et al.*, 1990; Dripps *et al.*, 1991). IL-1ra competitively inhibits the binding of IL-1 α and IL-1 β and thus acts as a specific inhibitor of IL-1 activity. Exogenously administered human recombinant IL-1ra can significantly reduce the severity of inflammation in many animal models of inflammatory disease, thus implicating IL-1 as an important mediator of inflammation in these models (Dinarello and Thompson, 1991). Endogenous IL-1ra plays an important role in reducing the severity of the inflammatory response by IL-1, since administration of neutralizing antibodies to IL-1ra causes an increase in severity and a prolongation of intestinal inflammation (Ferretti *et al.*, 1994).

Several studies utilizing site-directed mutagenesis have led to the identification of residues in IL-1 α and IL-1 β that are important for either receptor binding or receptor-mediated biological activity (MacDonald *et al.*, 1986; Gehrke *et al.*, 1990; Yamayoshi *et al.*, 1990; Ju *et al.*, 1991; Labriola-Tompkins *et al.*, 1991, 1993; Grutter *et al.*, 1994; Gayle *et al.*, 1993). An analysis of these results suggests there are two main sites on the surface of the IL-1 agonist molecules that are involved in receptor binding. One site (site A), located on the side of the β -barrel structure, was originally identified by mutagenesis of IL-1 β residue histidine 30 (His-30). Additional residues in this region have more recently been identified in both IL-1 α and IL-1 β . A second site (site B), approximately 20–25 Å from the first site, is located at the open end of the β -barrel and includes several charged residues, *e.g.* Arg-4, Lys-93, Lys-103, and Glu-105 of IL-1 β .

We report here the results of site-directed mutagenesis studies to identify residues on IL-1ra important for IL-1RI binding. Our results indicate that the IL-1ra residues homologous to receptor binding site A of IL-1 α and IL-1 β also play a role in IL-1RI binding of IL-1ra but that residues of IL-1ra homologous to receptor binding site B on IL-1 α and IL-1 β do not interact with the receptor. In addition, we believe that site A is the only receptor binding site on IL-1ra because we have mutagenized or deleted almost every residue on the surface of the molecule (a total of 103 residues) and found that only the residues of site A affect receptor binding. We have also performed site-directed mutagenesis of IL-1 β and found that site A on IL-1 β is larger than previously thought.

Our results indicate that the IL-1ra residues homologous to receptor binding site A of IL-1 α and IL-1 β also play a role in IL-1RI binding of IL-1ra but that residues of IL-1ra homologous to receptor binding site B on IL-1 α and IL-1 β do not interact with the receptor. In addition, we believe that site A is the only receptor binding site on IL-1ra because we have mutagenized or deleted almost every residue on the surface of the molecule (a total of 103 residues) and found that only the residues of site A affect receptor binding. We have also performed site-directed mutagenesis of IL-1 β and found that site A on IL-1 β is larger than previously thought.

EXPERIMENTAL PROCEDURES

Mutagenesis and Mutein Expression in *Escherichia coli*—Site-directed mutagenesis of IL-1ra and IL-1 β genes was performed using a Bio-Rad Mutagene kit. Muteins were expressed in *E. coli* and purified to near homogeneity from the soluble cell lysate as previously described (Eisenberg *et al.*, 1990). Protein concentrations were determined by BCA protein assay (Pierce), absorbance at 280 nm, and relative intensity of bands on a Coomassie-stained polyacrylamide gel.

* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

† To whom correspondence should be addressed. Tel.: 303-541-1333; Fax: 303-441-5535.

§ Present address: Pfizer Central Research, Dept. of Immunology, Bldg. 118C, Rm. 315C, Eastern Point Rd., Groton, CT 06340.

¶ Present address: Energy BioSystems Corp., 4200 Research Forest Dr., The Woodlands, Texas 77381.

** Present address: Dept. of Biochemistry and Molecular Biology, University of British Columbia, 2146 Health Science Mall, Vancouver, British Columbia V6T-1Z3, Canada.

¹ The abbreviations used are: IL-1, interleukin-1; IL-1ra, interleukin-1 receptor antagonist; IL-1RI, 80-kDa type 1 IL-1 receptor.

Competitive Receptor Binding Assays—Receptor binding assays were done as described (Hannum *et al.*, 1990). Briefly, a standard amount of ^{35}S -labeled IL-1ra at a concentration approximately equal to its K_d (150 pM) was incubated with mouse EL4 thymoma (ATCC, TIB181, ~5000 receptors per cell) or a Chinese hamster ovary cell line (kindly provided by R. Chizzonite) expressing the human type 1 IL-1 receptor (~30,000 receptors per cell) for 4 h at 4 °C with varying concentrations of cold competitor. The cells were harvested through a Millipore millititer plate filter system, and radioactivity retained on the filter was counted on an Ambis radioanalytical imaging system. Percent wild type activity was defined as $\text{IC}_{50}(\text{wild type})/\text{IC}_{50}(\text{mutant})$. The K_d for the wild type IL-1ra (as competitor) was estimated using a simplification of the Cheng-Prusoff relationship ($K_d = \text{IC}_{50}/2$, Cheng and Prusoff, 1973) and ranged from 150 to 400 pM, consistent with values previously reported. In each assay, a wild type control was included. All muteins were assayed a minimum of two times with the standard error between assays generally $\leq 25\%$.

NMR Spectroscopy Analysis of IL-1ra and Muteins—One-dimensional ^1H -labeled NMR spectra were collected for IL-1ra and several of its muteins. The spectra were recorded on a VXR500 spectrometer housed at the University of Colorado-Boulder. The 1.5 mM IL-1ra solutions (90% H_2O , 10% D_2O) were prepared in 10 mM phosphate (pH = 6.0), 100 mM NaCl, and 0.1 mM EDTA. Spectra were recorded at temperatures of 25, 30, and 35 °C. Each spectrum was collected with 8192 complex points over a spectral width of 7000 Hz, and a total of 64 transients were signal averaged for each free induction decay. All data were processed on a Sun 4260 using the NMR processing software FELIX (Hare Research). The spectra of IL-1ra wild type and mutants were plotted to allow for comparison of the backbone (H^α and H^β) and methyl proton chemical shifts and intensities.

Structure Modeling of IL-1 α —Since only the C- α coordinates of IL-1 α have been deposited in the Brookhaven Data base, we modeled possible side chain positions for comparison to IL-1 β and IL-1ra. Initial coordinates were assigned at random for missing atoms and then refined using simulated annealing in X-PLOR (Brunger *et al.*, 1987). Three different starting positions gave similar final conformations in all areas of interest.²

RESULTS

Mutagenesis of IL-1ra—Using site-directed mutagenesis, we replaced 93 of the 152 residues of IL-1ra and made two deletion mutants of 3 and 10 amino acids at the amino terminus. Initial single replacements were to glycine or alanine or, in a few instances, to an amino acid of the opposite charge. Muteins were assayed by competition with ^{35}S -labeled IL-1ra for binding to mouse EL4 cells or to Chinese hamster ovary cells expressing recombinant full-length human IL-1RI. From this initial round of mutagenesis, 54 of the muteins were assayed on EL4 cells, 33 were assayed on Chinese hamster ovary cells, and the remaining 6 were assayed on both cell lines.

For the vast majority of muteins, including the two deletion mutants, competition was not significantly different from that of the wild type protein (Fig. 1). The muteins that had less than 35% of wild type activity were investigated further. Five residues in IL-1ra were initially found to be sensitive to alanine or glycine substitution. Four of them, Trp-16, Gln-20, Tyr-34, and Tyr-147, were sensitive to substitution by other residues as well (Table I). At each of these residues, certain changes reduced receptor binding by 100-fold or more. These four residues form a contiguous patch on the IL-1ra surface, and two of them, Trp-16 and Tyr-34, correspond to residues Arg-11 and His-30, which have been previously identified as important in site A of IL-1 β . One of the four residues, Tyr-147, exhibited interesting receptor binding properties in that Y147G bound with lower affinity than wild type IL-1ra to human IL-1RI (34%) but with higher affinity to the mouse receptor (252%).

The fifth residue that exhibited $\leq 35\%$ of wild type activity in the initial screen, D74G, exhibited ~30% of wild type IL-1ra binding to the mouse IL-1RI but ~50% binding to the human receptor. Since muteins D74A, D74F, D74C, and D74W all

exhibit normal IL-1RI binding activity to the human receptor (data not shown), we believe that this residue is not fundamentally important for IL-1ra binding to IL-1RI.

One additional residue, Gln-36, was investigated further (despite the fact that Q36G exhibited normal binding on EL4 cells) due to the importance of the homologous residue on IL-1 β , Gln-32 (see below and Discussion). We found Q36F had only 1% of wild type activity (Table I), suggesting that this residue is also important for receptor binding. Gln-36 is adjacent to the four important residues discussed above.

The reduced affinity of muteins with changes at the five residues that make up the important binding site in IL-1ra (Trp-16, Gln-20, Tyr-34, Gln-36, and Tyr-147) suggests these residues contribute to the interaction of IL-1ra with IL-1RI. However, it is also possible that the mutations may disrupt the tertiary structure of the muteins, which causes a reduction in receptor affinity. To address this issue, we performed high resolution one-dimensional NMR on wild type IL-1ra and muteins Y34G, Q20A, and W16G. No significant differences were observed in the spectra of these four molecules, indicating there were no major differences among their structures. In addition, all muteins eluted at approximately the same salt concentration from an ion exchange column, suggesting that these molecules all have a similar conformation and overall charge.

Seven IL-1 β residues (Arg-4, Leu-6, Phe-46, Ile-56, Lys-93, Lys-103, and Glu-105) in the vicinity of the open end of the β -barrel have previously been shown to be important for binding to IL-1RI (Labriola-Tompkins *et al.*, 1991). Four of these seven are charged residues. Based on previously published sequence alignments (Stockman *et al.*, 1992), these charges are conserved in IL-1ra and have been suggested to be important for receptor binding. Thus, the homologous region of IL-1ra (Pro-50, Glu-52, His-54, Ser-89, Glu-90, Asn-91, Arg-92, Lys-93, Gln-94, Asp-95, Lys-96, Arg-102, Ser-103, Asp-104, Ser-105) was extensively mutagenized (Figs. 1 and 2, see also Vigers *et al.* (1994)) to investigate whether it had a similar function in the binding of IL-1ra to IL-1RI. Interestingly, none of the changes in this region of IL-1ra affected activity in the competitive receptor binding assay (Fig. 1).

An additional residue near the carboxyl terminus of these proteins, IL-1 α Asp-151, IL-1 β Asp-145, and IL-1ra Lys-145, has been characterized as important for biological activity but not for IL-1RI affinity. Of particular interest is the human IL-1ra mutein, K145D that has been shown to exhibit partial agonist activity on mouse cells but exhibits normal affinity for both the mouse and human receptors (Yamayoshi *et al.*, 1990; Ju *et al.*, 1991). This is consistent with our observation that replacing Lys-145 of IL-1ra with glycine has no effect on receptor binding activity (Fig. 1).

Site-directed Mutagenesis of IL-1 β —We performed site-directed mutagenesis on IL-1 β to reevaluate the role of the known site A residues and to examine other IL-1 β residues in the vicinity of this site. In addition, we wished to analyze residues in or near site B of IL-1 β .

We find that three residues in the region of site A appear to be important for binding IL-1 β to IL-1RI (Table II). Two residues, Gln-15 and His-30 of IL-1 β , align with IL-1ra residues Gln-20 and Tyr-34, which were identified as important from the mutagenesis of that protein. The third residue, Gln-32, corresponds to Gln-36 of IL-1ra, which was not originally identified by the scanning mutagenesis shown in Fig. 1. However, further mutagenesis of this residue in IL-1ra did suggest its importance in receptor binding (Table I).

Two IL-1 β residues in the vicinity of site A that interact only slightly or not at all with IL-1RI are Arg-11 and Thr-147.

² G. Vigers, unpublished data.




FIG. 1. Receptor binding activities of muteins of IL-1ra. Muteins were assayed as described under "Experimental Procedures" on either the mouse receptor (A) or the human receptor (B). The horizontal dashed line indicates 35% of wild type binding activity; muteins with activities below this value are denoted by an asterisk and were investigated further (see text). Their activities relative to wild type mouse and human IL-1RI are as follows: W16G, 22% mouse, 6% human; Q20G, 1% mouse; Q20A, 6% human; Y34G, 25% mouse, 25% human; D74G, 30% mouse; and Y147G, 35% human.

Others have previously reported that Arg-11 (which aligns with Trp-16 of IL-1ra) is not critical for receptor binding but is important for biological activity (Gehrke *et al.*, 1990). Our data are consistent with these observations. Thr-147 of IL-1 β aligns

structurally with the important IL-1ra residue Tyr-147 but is unimportant for IL-1 β binding to IL-1RI, possibly due to the distinct chemical nature of the side chains involved.

Site B residues in IL-1 β , Ile-56, Lys-93, and Glu-105 were all found to be sensitive to mutagenesis (Table II), consistent with previously reported data (Labriola-Tompkins *et al.*, 1991). An additional important residue in this region of IL-1 β is Lys-92 (Table II).

Location of Important Residues in IL-1ra, IL-1 α , and IL-1 β —Fig. 2 shows an alignment of human IL-1 α , IL-1 β , and IL-1ra, based on their three-dimensional structures. Highlighted on this alignment are the important residues for IL-1RI interaction identified by single-site mutagenesis, either in this work or previously by others. There are a number of key residues present on all three proteins in the equivalent spatial location. One residue that appears to be very important in all three proteins based on our mutagenesis data and the data from Gayle *et al.* (1993) is IL-1ra Gln-20, IL-1 β Gln-15, and IL-1 α Asn-29. Other residues important for binding IL-1 β and IL-1ra to the receptor but not critical for IL-1 α binding include IL-1 β His-30 and IL-1ra Tyr-34, homologous to IL-1 α Ala-44, and IL-1 β Gln-32 and IL-1ra Gln-36, which is homologous to IL-1 α His-46.


Fig. 3 shows the solvent-accessible surfaces based on the three-dimensional structures of IL-1 α , IL-1 β , and IL-1ra with the important binding site residues of each protein highlighted on the structure. There is a remarkable correspondence in the spatial location of site A on all three molecules and an interesting difference between the two agonist proteins and the antagonist protein at site B, in that this site is present in IL-1 α and IL-1 β but absent in IL-1ra.

For the three molecules, the total solvent-accessible areas of the binding site residues as indicated in Fig. 2 are approximately 650, 1440, and 330 Å² for IL-1 α , IL-1 β , and IL-1ra, respectively. The total solvent-accessible area of each molecule is approximately 7500 Å². Since all three molecules have the

TABLE I
Receptor binding activity of IL-1ra muteins
Receptor binding activity of muteins was determined on Chinese hamster ovary cells as described under "Experimental Procedures." Each number represents a single assay except in the case of muteins that were assayed more than twice, where the number is the mean \pm S.E. The number of assays performed is shown in parentheses.

IL-1ra mutein	Wild type activity
	%
W16G	12 \pm 3 (4)
W16K	<1, <1
W16M	5, 7
W16Q	9, 18
W16R	21 \pm 2 (3)
W16Y	53, 85
Q20A	6, 8
Q20Y	<1, <1
Q20D	<1, <1, <1
Q20K	<1, <1
Q20M	18, 22
Q20N	43, 46
Y34G	21, 23
Y34K	<1, <1
Y34D	7, 11
Y34H	80, 84
Y34W	88, 98
Y34M	86, 100
Q36F	<1, <1
Y147G	24, 44
Y147K	<1, <1
Y147T	3, 5
Y147H	41, 69
Y147M	63, 69

FIG. 2. Residues in IL-1 α , IL-1 β , and IL-1ra identified by single-site mutagenesis as important for receptor interaction. Sequences are aligned as in Vigers *et al.* (1994), based on x-ray structures. Important residues are indicated by the following symbols: ♦, IL-1 α (Yamayoshi *et al.*, 1990; Kawashima *et al.*, 1991; Gayle *et al.*, 1993; Labriola-Tompkins *et al.*, 1993); ■, IL-1 β (MacDonald *et al.* (1986), Gehrke *et al.* (1990), Labriola-Tompkins *et al.* (1991), Grutter *et al.* (1994), Ju *et al.* (1991), and this work); ●, IL-1ra (Ju *et al.* (1991) and this work). Shaded residues are in β -strands according to Graves *et al.* (1990) for IL-1 α , Priestle *et al.* (1989) for IL-1 β , and Vigers *et al.* (1994) for IL-1ra.



same affinity for the IL-1RI, one can conclude that IL-1ra generates more binding energy from site A than do IL-1 α or IL-1 β . To check whether the single site A of IL-1ra could account for the observed binding affinity, we applied the equations $\Delta G = -RT \ln(K)$ and $\Delta\Delta G = -RT \ln(K_1/K_2)$ to the observed binding equilibria. We find that the wild type IL-1ra has a change in free energy upon binding of approximately 52 kJ/mol. Considering only the neutral mutations of Trp-16, Gln-20, Tyr-34, and Tyr-147 to glycine (Table I), the four residues at the center of site A in IL-1ra account for at least 18.3 kJ/mol binding energy. If we consider the more extreme mutations to these four residues, *e.g.* W16K, and include Q36F, we can account for >53 kJ/mol. Thus there is reasonably close agreement between these numbers, considering the broad assumptions made in the calculations.

DISCUSSION

A simple way of defining the regions of a protein important for receptor binding is through the use of *in vitro* site-directed

TABLE II
Receptor binding activity of IL-1 β mutants

Receptor binding activity of mutants was determined on Chinese hamster ovary cells as described under "Experimental Procedures." Numbers represent the mean of at least two assays.

IL-1 β mutant	Wild type activity
	%
R11G ^a	45
R11A ^a	55
Q15G ^a	<1
Q15H ^a	130
H30G ^a	<1
H30E ^a	2
H30A ^a	10
H30S ^a	10
Q32G ^a	<1
I56G ^b	10
K92G ^b	8
K93G ^b	<1
K93M ^b	<1
K93Q ^b	5
E105G ^b	30
T147G ^a	70

^a Site A residues.

^b Site B residues.

mutagenesis. This method has been used over the past few years by several groups to identify residues involved in the high affinity binding of IL-1 α and IL-1 β to IL-1RI. These studies have led to the conclusion that two distinct receptor binding regions (site A and site B) are present on both IL-1 α and IL-1 β . Site A, located on the side of the β -barrel structure, was originally identified by the mutagenesis of IL-1 β residues His-30 (MacDonald *et al.*, 1986) and Arg-11 (Gehrke *et al.*, 1990). Recently, additional residues in this region have been identified on IL-1 α (Gayle *et al.*, 1993) and on IL-1 β (Grutter *et al.*, 1994). We have extensively mutagenized IL-1ra and identified only five residues, Trp-16, Gln-20, Tyr-34, Gln-36, and Tyr-147, that are important for binding to the IL-1RI. These five residues, when changed to glycine, were also found to be important for binding to recombinant soluble human IL-1RI using surface plasmon resonance technology on a BIAcore instrument. Glycine substitutions at other positions had no significant effect on binding to human IL-1RI either on the surface of cells or to the purified receptor on the BIAcore.³ All of these important amino acids map to site A, which is conformationally conserved among the IL-1 family members.

The chemical nature of the IL-1ra site A side chains is critical for high affinity binding to IL-1RI, as shown by the effect of amino acid substitution on binding. In addition to identifying substitutions that lead to a significant loss in binding, we have found some substitutions that have little or no effect on binding. In this regard, we show that replacing the aromatic amino acids Trp-16 and Tyr-34 in IL-1ra with other aromatic amino acids has no significant effect on binding. It is also interesting to note that Tyr-34 of IL-1ra can be replaced with histidine, which is the corresponding residue in IL-1 β , with no loss in binding, and Gln-20 of IL-1ra can be replaced with asparagine, which is the corresponding IL-1 α residue, with only a moderate loss in binding. In addition, Gln-20 and Gln-36 of IL-1ra correspond to Gln-15 and Gln-32 of IL-1 β , based on the three-dimensional structures of these molecules. In light of the chemical similarity of site A among these proteins and the effect of mutagenesis of residues comprising this site, it appears that this region is both structurally and functionally homologous among the three IL-1 family members.

³ D. J. Dripps and J. Jordan, unpublished data.




FIG. 3. Receptor binding sites in the IL-1 family. Comparison of the three-dimensional structure solvent-accessible surface of IL-1 α , IL-1 β , and IL-1ra showing the residues important for receptor interaction in red. Site A (common to all three proteins) is on the top of the molecules, and site B (found in IL-1 α and IL-1 β only) is near the bottom. Residues colored are the same as those marked in Fig. 2.




FIG. 4. A model of receptor binding and activation. The agonists, IL-1 α and IL-1 β , contact two sites on the receptor causing activation (indicated by the spiral), whereas IL-1ra contacts only one site and does not activate (indicated by the straight line).

The second receptor binding region (site B) is located at the open end of the β -barrel and includes IL-1 β residues Arg-4, Lys-6, Phe-46, Ile-56, Lys-92, Lys-93, Lys-103, and Glu-105 and IL-1 α residues Arg-16, Ile-18, Asp-64, Asp-65, Ile-68, Lys-100, Asn-108, Trp-113, Gly-17, and Gln-136 (Labriola-Tompkins *et al.*, 1991, 1993). The area in IL-1ra that is structurally analogous to site B of IL-1 β is not involved in binding to IL-1RI. A careful comparison of IL-1 β and IL-1ra in this region revealed very significant structural differences between the two molecules (Vigers *et al.*, 1994). Thus, the difference in function in this region between the agonists and the antagonist is consistent with this being the region exhibiting the greatest difference in structure between these two classes of protein.

Through the extensive use of site-directed mutagenesis, we have demonstrated that the IL-1 antagonist is missing one of the two receptor binding regions identified on the two IL-1 agonists. This finding suggests a model for receptor activation in which IL-1 α and IL-1 β , by contacting two sites on IL-1RI, causes activation, but IL-1ra, in making contacts with the receptor at only one of the two receptor binding sites, is unable to induce an IL-1-like signal (Fig. 4). An alternative model, in which the IL-1 agonists act by dimerizing two IL-1 receptor molecules, as in the case of human growth hormone (Wells *et al.*, 1993), or by forming a heterodimer of IL-1RI and the recently identified IL-1 receptor accessory protein (Greenfeder *et al.*, 1994) is also possible and is consistent with the observation that IL-1ra binds with a substantially higher affinity to the soluble form of IL-1RI than either IL-1 α or IL-1 β (Swenson *et al.*, 1993). However, dimerizing two IL-1RI molecules seems unlikely because attempts to demonstrate the involvement of aggregation of IL-1RI by either IL-1 α or IL-1 β in receptor activation have been unsuccessful (Slack *et al.*, 1993). In addition, binding experiments with IL-1 β mutants and soluble IL-1RI on the BIAcore indicate that site A and site B residues both interact with the purified IL-1RI.⁴

IL-1ra binds to IL-1RI with the same affinity as the IL-1 agonists but uses only one binding site instead of two. Since site A of IL-1ra is compact and generates high affinity binding with the IL-1RI, it may act as a template for rational design for a small molecule IL-1 antagonist. Such a small molecule is

likely to contain pharmacophoric elements that match side-chain atoms of the site A residues. Additional structure-function studies are being done to further discern how these side chain atoms of IL-1ra contact residues in IL-1RI.

Acknowledgments—We thank Richard Chizzonite for kindly providing the cell line expressing the human IL-1RI, Marlyn Troetsch for expert technical assistance, and Hiko Kohno for useful critique of the manuscript.

REFERENCES

- Brünger, A., Kuriyan, J., and Karplus, M. (1987) *Science* **235**, 458–460
- Carter, D. B., Deibel, M. R., Jr., Dunn, C. J., Tomich, C.-S. C., Laborde, A. L., Slightom, J. L., Berger, A. E., Bienkowski, M. J., Sun, F. F., McEwan, R. N., Harris, P. K. W., Yem, A. W., Waszak, G. A., Chosay, J. G., Sieu, L. C., Hardee, M. M., Zurcher-Neely, H. A., Reardon, I. M., Heinrichson, R. L., Truesdell, S. E., Shelly, J. A., Eessalu, T. E., Taylor, B. M., and Tracey, D. E. (1990) *Nature* **344**, 633–638
- Cheng, Y., and Prusoff, W. H. (1973) *Biochem. Pharmacol.* **22**, 3099–3108
- Dinareello, C. A. (1991) *Blood* **77**, 1627–1652
- Dinareello, C. A., and Thompson, R. C. (1991) *Immunol. Today* **12**, 404–410
- Dripps, D. J., Brandhuber, B. J., Thompson, R. C., and Eisenberg, S. P. (1991) *J. Biol. Chem.* **266**, 10331–10336
- Eisenberg, S. P., Evans, R. J., Arend, W. P., Verderber, E., Brewer, M. T., Hannum, C. H., and Thompson, R. C. (1990) *Nature* **343**, 341–346
- Eisenberg, S. P., Brewer, M. T., Verderber, E., Heimdal, P., Brandhuber, B. J., and Thompson, R. C. (1991) *Proc. Natl. Acad. Sci. U. S. A.* **88**, 5232–5236
- Ferretti, M., Casini-Raggi, V., Pizarro, T. T., Eisenberg, S. P., Nast, C. C., and Cominelli, F. (1994) *J. Clin. Invest.* **94**, 449–453
- Gayle, R. B., III, Poindexter, K., Cosman, D., Dower, S. K., Gillis, S., Hopp, T., Jerzy, R., Kronheim, S., Lum, V., Lewis, A., Goodgame, M. M., March, C. J., Smith, D. L., and Srinivasan, S. (1993) *J. Biol. Chem.* **268**, 22105–22111
- Gehrke, L., Jobling, S. A., Paik, L. S. K., McDonald, B., Rosenwasser, L. J., and Auron, P. E. (1990) *J. Biol. Chem.* **265**, 5922–5925
- Graves, B. J., Hatada, M. H., Hendrickson, W. A., Miller, J. K., Madison, V. S., and Satow, Y. (1990) *Biochemistry* **29**, 2679–2684
- Greenfeder, S., Chizzonite, R., Ju, G. (1994) *J. Cell. Biochem.* **18**, (suppl.) 217
- Grütter, M. G., van Oostrum, J., Priestle, J. P., Edelmann, E., Joss, U., Feige, U., Vosbeck, K., and Schmitz, A. (1994) *Protein Eng.* **7**, 663–671
- Hannum, C. H., Wilcox, C. J., Arend, W. P., Joslin, F. G., Dripps, D. J., Heimdal, P. L., Armes, L. G., Sommer, A., Eisenberg, S. P., and Thompson, R. C. (1990) *Nature* **343**, 336–340
- Ju, G., Labriola-Tompkins, E., Campen, C. A., Benjamin, W. R., Karas, J., Plocinski, J., Biondi, D., Kaffka, K. L., Kilian, P. L., Eisenberg, S. P., and Evans, R. J. (1991) *Proc. Natl. Acad. Sci. U. S. A.* **88**, 2658–2662
- Kawashima, H., Yamagishi, J., Yamayoshi, M., Ohue, M., Fukui, T., Kotani, H., and Yamada, M. (1991) *Protein Eng.* **5**, 171–172
- Labriola-Tompkins, E., Chandran, C., Kaffka, K. L., Biondi, D., Graves, B. J., Hatada, M., Madison, V. S., Karas, J., Kilian, P. L., and Ju, G. (1991) *Proc. Natl. Acad. Sci. U. S. A.* **88**, 11182–11186
- Labriola-Tompkins, E., Chandran, C., Varnell, T. A., Madison, V. S., and Ju, G. (1993) *Protein Eng.* **6**, 535–539
- MacDonald, H. R., Wingfield, P., Schmeissner, U., Shaw, A., Clor, G. M., and Gronenborn, A. M. (1986) *FEBS Lett.* **209**, 295–298
- Murzin, A. G., Lesk, A. M., and Chothia, C. (1992) *J. Mol. Biol.* **223**, 531–543
- Priestle, J. P., Schär, H. P., and Grütter, M. G. (1989) *Proc. Natl. Acad. Sci. U. S. A.*

⁴ P. Caffes and R. J. Evans, unpublished data.

- 86, 9667-9671
- Sims, J. E., Gayle, M. A., Slack, J. L., Alderson, M. R., Bird, T. A., Giri, J. G., Colotta, F., Re, F., Mantovani, A., Shanebeck, K., Grabstein, K. H., and Dower, S. K. (1993) *Proc. Natl. Acad. Sci. U. S. A.* 90, 6155-6159
- Slack, J., McMahan, C. J., Waugh, S., Schooley, K., Spriggs, M. K., Sims, J. E., and Dower, S. K. (1993) *J. Biol. Chem.* 268, 2513-2524
- Stockman, B. J., Scabill, T. A., Roy, M., Ulrich, E. L., Strakalaitis, N. A., Brunner, D. P., Yem, A. W., and Deibel, M. R., Jr. (1992) *Biochemistry* 31, 5237-5244
- Svenson, M., Hansen, M. B., Heegaard, P., Abell, K., and Bendtzen, K. (1993) *Cytokine* 5, 427-435
- Vigers, G. P. A., Caffes, P., Evans, R. J., Thompson, R. C., Eisenberg, S. P., and Brandhuber, B. J. (1994) *J. Biol. Chem.* 269, 12874-12879
- Wells, J. A., Cunningham, B. C., Fuh, G., Lowman, H. B., Bass, S. H., Mulkerrin, M. G., Ultsch, M., and deVos, A. M. (1993) *Recent Prog. Horm. Res.* 48, 253-275
- Yamayoshi, M., Ohue, M., Kawashima, H., Kotani, H., Iida, M., Kawata, S., and Yamada, M. (1990) *Lymphokine Res.* 9, 405-413




Figure 4 Live video observation of the Mei2-GFP dot in meiotic prophase. A diploid cell generated by conjugation was monitored. Three images taken at 2-min intervals are shown. Red regions, nuclear DNA; yellow spots, fluorescence of Mei2-GFP. The whole-cell body is faintly visible in red. Scale bar, 5 μ m.

Expression vectors. pREP1 carries the authentic thiamine-repressible *nmt1* promoter, whereas pREP41 and pREP81 carry its modified versions, the expression of which is respectively 10-fold and 100-fold lower than that of pREP1 (ref. 22). To express full-length *mei2* from the *nmt1* promoter, an *NdeI* site was created at the initiation codon of the *mei2* open reading frame (ORF) and a 2.6-kb *NdeI*–*BglII* fragment was cloned into pREP vectors. Integration of *nmt1*–*mei2*⁺ or *nmt1*–*mei2*–SATA on pREP41 into the chromosomal *leu1* locus was done, as described²³. We used minimal medium SD with 1% glucose, which contains thiamine (1.2 μ M), to repress the *nmt1* promoter, and minimal medium MM with 1% glucose to derepress it. Cell growth and sporulation were monitored on synthetic agar plates SSA with or without 2 μ M thiamine (see ref. 12 for more details of the media).

In vitro kinase assay and tryptic phosphopeptide mapping. Full-length Pat1²⁴ and full-length Mei3⁴, each fused to GST, were used in the *in vitro* phosphorylation assay. The assay was carried out as follows: 3 pmol of GST–Mei2 was mixed with 0.2 pmol GST–Pat1 and 2 μ g BSA in K buffer (150 mM Tris–HCl, pH 7.5, 20 mM MgCl₂, 10 mM MnCl₂, 15 mM 2-mercaptoethanol). The reaction was initiated by adding 20 μ M [γ -³²P]ATP and terminated by adding SDS–PAGE buffer after 30 min incubation at 30 °C. To label Mei2 protein *in vivo*, we transformed *mei2* Δ *pat1*⁺ and *mei2* Δ *pat1* Δ haploid strains with pREP41–*mei2*–FA, carrying the inactive F644A allele¹² (Fig. 1a). *mei2*–FA, rather than *mei2*⁺, was used here because viable transformants could be obtained from a *pat1* Δ strain. Transformed cells were labelled with ortho-[³²P]-phosphate for 18 h in MM liquid, collected by centrifugation, and broken in 10% TCA with glass beads. After washing with acetone, the pellet was dissolved in S buffer (50 mM Tris–HCl, pH 7.5, 1 mM EDTA, 1 mM 2-mercaptoethanol, 0.5 mM PMSF, 1% SDS). An aliquot of the supernatant was immunoprecipitated with anti-Mei2 antibodies¹². The immunocomplex was resolved by SDS–PAGE and the Mei2 band eluted from the gel and digested with trypsin as described²⁵. GST–Mei2C phosphorylated *in vitro* was processed similarly. Tryptic samples were applied to thin-layer cellulose plates and separated by high-voltage electrophoresis (at 1,000 V) at pH 1.9 for 30 min, followed by ascending chromatography.

Screening for *mei2* alleles encoding constitutively active gene products. We randomly mutagenized the C-terminal half of *mei2* encoding residues 429–750 by polymerase chain reaction (PCR) and expressed their full-length versions from pREP41 in wild-type haploid cells. Three relatively weak

'activated' *mei2* alleles, which could induce haploid meiosis upon induction of transcription, were isolated and sequenced.

Fluorescence microscopy of GFP-tagged Mei2 protein. We cloned a mutant version (Ser65 \rightarrow Thr) of GFP²⁶ into pREP81, and inserted an *NdeI*–*Sall* fragment carrying the exact *mei2* ORF before the GFP ORF. The fusion protein Mei2–GFP was expressed in *mei2* Δ cells to eliminate the competitive effects of endogenous Mei2 protein. Living cells were counterstained with Hoechst 33342 and video-recorded by a Peltier-cooled CCD camera (Photometrics) attached to an Olympus inverted microscope IMT-2, as described^{18,27}.

Received 4 November 1996; accepted 13 January 1997.

1. Iino, Y. & Yamamoto, M. *Mol. Gen. Genet.* **198**, 416–421 (1985).
2. Nurse, P. *Mol. Gen. Genet.* **198**, 497–502 (1985).
3. Beach, D., Rodgers, L. & Gould, J. *Curr. Genet.* **10**, 297–311 (1985).
4. McLeod, M., Stein, M. & Beach, D. *EMBO J.* **6**, 729–736 (1987).
5. McLeod, M. & Beach, D. *Nature* **332**, 509–514 (1988).
6. Yamamoto, M. *Trends Biochem. Sci.* **21**, 18–22 (1996).
7. Eberhart, C. G., Maines, J. Z. & Wasserman, S. A. *Nature* **381**, 783–785 (1996).
8. Egel, R. in *Molecular Biology of the Fission Yeast* (eds Nasim, A. et al.) 31–73 (Academic, San Diego, 1989).
9. Iino, Y. & Yamamoto, M. *Proc. Natl Acad. Sci. USA* **82**, 2447–2451 (1985).
10. Watanabe, Y., Iino, Y., Furuhashi, K., Shimoda, C. & Yamamoto, M. *EMBO J.* **7**, 761–767 (1988).
11. Birney, E., Kumar, S. & Krainer, A. R. *Nucleic Acids Res.* **12**, 5803–5816 (1993).
12. Watanabe, Y. & Yamamoto, M. *Cell* **78**, 487–498 (1994).
13. Robinson, S., Campos, A., Yao, K. & White, K. *Science* **242**, 1570–1572 (1988).
14. Nakashima, N., Tanaka, K., Sturm, S. & Okayama, H. *EMBO J.* **14**, 4794–4802 (1995).
15. Fernandez-Sarabia, M. J., McInerney, C., Harris, P., Gordon, C. & Fantes, P. *Mol. Gen. Genet.* **238**, 241–251 (1993).
16. Sugiyama, A., Tanaka, K., Okazaki, K., Nojima, H. & Okayama, H. *EMBO J.* **13**, 1881–1887 (1994).
17. Chalfie, M., Tu, Y., Euskirchen, G., Ward, W. W. & Prasher, D. C. *Science* **263**, 802–805 (1994).
18. Chikashige, Y. et al. *Science* **264**, 270–273 (1994).
19. Bohmann, K., Ferreira, J., Santama, N., Weis, K. & Lamond, A. I. *J. Cell Sci.* (suppl.) **19**, 107–113 (1995).
20. Li, P. & McLeod, M. *Cell* **87**, 869–880 (1996).
21. Sugimoto, A., Iino, Y., Maeda, T., Watanabe, Y. & Yamamoto, M. *Genes Dev.* **5**, 1990–1999 (1991).
22. Basi, G., Schmidt, E. & Maundrell, K. *Gene* **123**, 131–136 (1993).
23. Mochizuki, N. & Yamamoto, M. *Mol. Gen. Genet.* **233**, 17–24 (1992).
24. McLeod, M. & Beach, D. *EMBO J.* **5**, 3665–3671 (1986).
25. Boyle, W. J., Geer, P. V. d. & Hunter, T. *Meth. Enzymol.* **201**, 110–149 (1991).
26. Heim, R., Cubitt, A. B. & Tsien, R. Y. *Nature* **373**, 663–664 (1995).
27. Hiraoka, Y., Swedlow, J. R., Paddy, M. R., Agard, D. A. & Sedat, J. W. *Semin. Cell Biol.* **2**, 153–165 (1991).
28. Shimoda, C. et al. *J. Bacteriol.* **169**, 93–96 (1987).
29. Takeda, T. & Yamamoto, M. *Proc. Natl Acad. Sci. USA* **84**, 3580–3584 (1987).

Acknowledgements. We thank A. Mayeda and M. Yanagida for discussion and advice, P. Fantes for the *cdc22* clone, H. Okayama for the *rep2* clone, Y. Watanabe for GFP DNA, and D. A. Hughes and P. Nurse for help in preparation of the manuscript. This work was supported by Grants-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Science, Sports and Culture of Japan.

Correspondence and requests for materials should be addressed to M.Y. (e-mail: myamamoto@ims.u-tokyo.ac.jp).

Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1 β

Guy P. A. Vigers, Lana J. Anderson, Patricia Caffes & Barbara J. Brandhuber

Amgen Inc., 3200 Walnut Street, Boulder, Colorado 80301, USA

Interleukin-1 (IL-1) is an important mediator of inflammatory disease. The IL-1 family currently consists of two agonists, IL-1 α and IL-1 β , and one antagonist, IL-1ra. Each of these molecules binds to the type I IL-1 receptor (IL1R)¹. The binding of IL-1 α or IL-1 β to IL1R is an early step in IL-1 signal transduction and blocking this interaction may therefore be a useful target for the development of new drugs. Here we report the three-dimensional structure of IL-1 β bound to the extracellular domain of IL1R (s-IL1R) at 2.5 Å resolution. IL-1 β binds to s-IL1R with a 1:1 stoichiometry. The crystal structure shows that s-IL1R consists of three immunoglobulin-like domains which wrap around IL-1 β in a manner distinct from the structures of previously described cytokine–receptor complexes. The two receptor-binding regions

on IL-1 β identified by site-directed mutagenesis^{2,3} both contact the receptor: one binds to the first two domains of the receptor, while the other binds exclusively to the third domain.

Human IL1R was first cloned from T cells⁴ and its sequence predicted a mature receptor consisting of a 552 amino-acid protein containing an extracellular ligand-binding domain of 319 amino acids having three immunoglobulin-like (Ig-like) domains, a single transmembrane segment, and a 213 amino-acid cytoplasmic domain. IL-1 α , IL-1 β and IL1RA (IL-1 receptor antagonist) all bind to IL1R and although they share only about 25% amino-acid sequence identity, these molecules all have the same β -trefoil, 12-stranded β -barrel structure⁵. In order to further our understanding of IL-1-IL1R interactions we have solved the crystal structure of recombinant human IL-1 β bound to recombinant human s-IL1R. The current structure has an *R*-factor of 23.2% at 2.5 Å resolution.

The IL-1 β -s-IL1R complex structure (Fig. 1) was solved using a combination of molecular replacement and multiple isomorphous replacement (MIR) phasing methods (Table 1). The complex has rough dimensions of 97 Å × 52 Å × 35 Å with one s-IL1R molecule wrapping around the IL-1 β molecule to contact both the receptor binding sites previously identified by structure: function studies^{2,3}. As predicted by its sequence, s-IL1R has three Ig-like domains (see Fig. 1). All three Ig-like domains contain a conserved pair of cysteines and a tryptophan residue about 14 residues after the first conserved cysteine of each domain. Domain 3 is of the c-type, seven-stranded variety⁶, similar to the immunoglobulin (Ig) constant domain whereas domains 1 and 2 are more unusual topologically. In both of these domains, strand a is strand-switched to the 'front' face of the barrel, as seen in some v-type Igs, but the c' strand is very short (as in constant domains) and the c'' strand is not detectable. Strands d and e are also extremely short, and are comparable in length to those seen in the cell-adhesion molecule *N*-cadherin⁷ (Protein Database (PDB) entry 1NCG). Furthermore, strands c, d and e are on the distal side of domains 1 and 2 from the IL-1 β molecule, and are not involved in IL-1 binding. Thus, all three domains of the IL1RI are most simply classified as c-type. Domains 1 and 2 are closely juxtaposed, with a disulphide bond (C104-

C147) holding them together, whereas domain 3 is connected by a 5-residue linker (L201-K205). Domain 3 provides a 'lid' which covers most of the top of the IL-1 β β -barrel, whereas domains 1 and 2 form a groove which binds to the lower rim of the barrel.

The structure of IL-1 β does not change substantially upon binding. The r.m.s. deviation in position for all non-hydrogen atoms is 1.76 Å between the starting structure of IL-1 β ⁸ and the refined complex structure. Maximum differences are seen at Q32 (r.m.s.d. = 5.6 Å), K88 (r.m.s.d. = 5.5 Å), Q141 (r.m.s.d. = 4.3 Å) and the C-terminal S153 (r.m.s.d. = 9.6 Å). Of these residues, Q32 is involved in receptor binding, whereas the other three are in flexible loops of the molecule. Minimum differences are seen in residues such as A59, L60, F112 and F133 (all about 0.2 Å r.m.s.d.) which are involved in the packing of the hydrophobic core of the IL-1 β ⁵.

Extensive site-directed mutagenesis work has delineated two receptor-binding sites on IL-1 α and IL-1 β and one on IL1RA. Figure 2 shows that on IL-1 β the two binding sites correspond extremely well with residues buried in the receptor: ligand interface. For example, Gln 15 (shown in blue in the middle of Fig. 2) lost 100% of its IL1R binding activity when mutated to glycine, and 116 Å² of its solvent-accessible surface is buried upon binding s-IL1R. In addition, numerous residues, which showed a loss of 30–50% of their receptor binding activity upon conservative mutation, are located on the edges of the binding sites and show corresponding changes in computed solvent accessibility upon receptor binding. These results demonstrate the utility of mutagenesis studies for mapping ligand: receptor contacts.

The binding site common to all three IL-1 family members, on the 'side' of the IL-1 β β -barrel (site A), makes contacts with β -strands a1, a2, b2 and the b2-c2 loop in domains 1 and 2 of the receptor (Fig. 1) and consists of residues 11, 13–15, 20–22, 27, 29–36, 38, 126–131, 147 and 149. The critical binding residues Arg 11 and Gln 15 contact domain 2 whereas His 30 and Gln 32 bind in the domain 1–2 junction. The surface of the receptor at this binding site has a number of pockets that will accept side chains of IL-1 β . Thus a significant component of the binding energy at this site probably




Figure 1 Left, Ribbon diagram of s-IL1R complexed to IL-1 β . Domains 1, 2 and 3 of s-IL1R are coloured light, medium and dark blue, respectively. IL-1 β is yellow, with site A residues in green and site B residues in red. Middle, Ribbon diagram of the structure of IL-1 β bound to s-IL1R. The β -strands are shown as arrowed ribbons in green, α -helices are red, and the connecting loops are purple. The structure is

oriented so that the carboxy terminus of s-IL1R and the cell membrane, if present, are at the bottom of the picture. Right, Topology diagram of s-IL1R. The IL-1 β -binding elements in site A and site B are coloured green and red, respectively. Secondary structural elements are not to scale.

comes from van der Waals contacts between IL-1 β and s-IL1R. Interestingly, the position of Gln 32 has moved by more than 5 Å from its position in the unliganded X-ray structure, and now fits in a deep pocket on the s-IL1R (Fig. 3).

Site B, the second binding site identified on IL-1 α and IL-1 β but not IL1RA, is on the top of the β -barrel and is formed by residues 1–4, 6, 46, 48, 51, 53–54, 56, 92–94, 103, 105–106, 108, 109, 150 and 152. Site B makes contacts only with domain 3 of s-IL1R. Previous work from our group⁵ suggested that site B of IL-1 β was composed of a 'horseshoe' of hydrophilic residues surrounding several hydrophobic residues. As shown in Fig. 3, both the hydrophilic residues (Arg 4, Gln 48, Glu 51, Asn 53, Lys 93, Glu 105 and Asn 108) and the hydrophobic residues (Leu 6, Phe 46, Ile 56 and Phe 150) do indeed contact IL1R over a large and relatively flat surface (formed by β -strands c3, d3, f3, g3 and the b3–c3, c3–d3, f3–g3 and g2–a3 loops), which is complementary to IL-1 β in hydrophobicity. Thus, the binding energy of site B appears to be more dependent upon hydrophobic and hydrophilic interactions than in site A. Because IL1RA lacks the distinctive 'horseshoe' feature of IL-1 β , formation

of the IL1RI-IL1RA complex will presumably not make the same energetically favourable site B contacts seen in this structure.

Calculating the changes in solvent-accessible area of the IL-1 β on binding s-IL1R, 1,087 Å² are buried in site A over 25 residues and 1,001 Å² in site B over 21 residues, for a total of 2,088 Å² overall. In addition to the hydrophilic–hydrophobic interactions described above (which are particularly apparent for site B), both binding sites also make extensive use of salt bridges and hydrogen bonds. Site A and site B have 10 and 13 salt bridges, respectively, and both sites also contain seven intramolecular hydrogen bonds (as deduced from the X-ray structure). It is interesting to note that in this complex, the ligand-binding interactions are with the β -strands in the faces of the Ig-like domains, not with the 'elbow' formed by the loops between the domains, as seen in the structures of interferon- γ –interferon- γ receptor⁹, human growth hormone–human growth hormone-binding protein¹⁰ (PDB entry 3HHR) and the erythropoietin mimetic peptide–erythropoietin-binding protein¹¹ (PDB entry 1EBP). Also, in previously determined cytokine–receptor structures, whereas the cytokine might exist as a monomer




Figure 2 Surface representations of IL-1 β . Left, Structure of unbound IL-1 β *, spectral colouring based on site-directed mutagenesis experiments. Blue residues lost 100% of IL1R binding activity, red residues lost no activity, and grey residues were not done. Right, Structure of IL-1 β from the complex coloured to

show the change in solvent-accessible area upon complex formation¹⁶. Blue residues bury 100 Å² or greater, and red residues bury 2 Å². Grey residues bury less than 2 Å². Site B is at the top and site A faces the viewer.

Table 1 MIR data

Data set	Resolution (Å)	R_{sym} (last shell)	Completeness (last shell)	$\langle I/\sigma(I) \rangle$ (last shell)	Sites (<i>n</i>)	$R_{\text{cutoffs_a}}$	$R_{\text{cutoffs_c}}$	$R_{\text{cutoffs_ano}}$	Phasing power_a	Phasing power_c
Native*	2.5	6.6 (10.4)	96.2 (94.9)	28.03 (10.94)	–	–	–	–	–	–
HgCl2_1	3.0	7.5 (27.2)	79.3 (29.5)	15.11 (5.46)	2	50.0	48.0	70.0	2.0	1.7
HgCl2_2	2.8	8.1 (31.4)	97.4 (98.5)	13.74 (4.51)	2	64.0	62.0	70.0	1.5	1.2
PtCl_1	3.0	6.1 (27.6)	84.4 (91.6)	15.31 (4.55)	5	76.0	66.0	60.0	1.1	1.0
PtCl_2	3.0	7.8 (30.7)	76.5 (80.4)	15.07 (5.33)	5	75.0	68.0	80.0	1.2	1.1
C71S_1†	3.0	7.2 (19.8)	74.7 (80.3)	14.15 (6.23)	1	63.0	62.0	80.0	1.6	1.2
C71S_2†	2.5	6.6 (19.6)	93.0 (95.2)	16.66 (5.79)	1	72.0	71.0	80.0	1.4	1.1
Q126C_1‡	3.0	7.3 (23.7)	78.7 (85.8)	15.93 (5.95)	2	74.0	63.0	80.0	1.1	1.0
Q126C_2‡	2.5	4.9 (18.3)	94.3 (97.2)	17.90 (6.85)	2	86.0	78.0	80.0	0.9	0.8

* Data merged from two data sets.

† IL-1 β mutated so that cysteine 71 is serine.

‡ IL-1 β mutated so that cysteine 71 is serine and glutamine 126 is cysteine.




Figure 3 Stereoscopic surface representations of s-IL1R and ribbon diagrams of IL-1 β . Top, Site A. Bottom, Site B. Side chains in IL-1 β and the surface of s-IL1R are

coloured red for hydrophobic residues and purple for hydrophilic residues. The IL-1 β backbone ribbon is yellow.

(hGH), dimer (IFN γ) or trimer (TNF β)¹², in every case two or more receptors bound to the cytokine and each receptor made a single contiguous surface contact with the cytokine. The s-IL1R binding motif thus provides a new model for receptor–cytokine interactions.

IL-1 signalling is believed to result from the formation of a ternary complex consisting of an IL-1 agonist, IL1R and IL1R accessory protein (IL1RAcP)¹³. When IL1RA binds IL1R, the ternary complex is not formed and signalling does not occur. Formation of the ternary complex therefore presumably requires an epitope that is created when IL1RI binds IL-1 β but not IL1RA. Whether the epitope is created by formation of the receptor–ligand interface, or by conformational changes of IL1RI on complex formation, has yet to be determined. Site-directed mutagenesis of additional surface residues in IL-1 and IL1R, and solving the structure of the ternary complex, will further advance our understanding of the IL-1 family members' activities. □

Methods

Purification and crystallization. Recombinant human s-IL1R (residues 1–315, GenBank numbering) was expressed in *Escherichia coli*, refolded and purified using an IL1RA affinity column, MonoQ ion-exchange column and gel filtration column (B.J.B. *et al.*, manuscript in preparation). Wild-type and mutants of IL-1 β used for heavy-atom phasing were generated and purified as described previously³. The mercury chloride derivative was found to derivatize the cysteines only in IL-1 β , therefore cysteine mutants of IL-1 β were made to augment the phase information available. All mutants that were crystallized and derivatized were isomorphous with native, wild-type complex crystals. The s-IL1R was incubated overnight in a fivefold molar excess of IL-1 β , purified over a Superdex 75 column and concentrated to 5 mg ml⁻¹. Crystals were grown by hanging-drop diffusion against 1.8 M ammonium sulphate, 100 mM MES pH 6.0 at 0–4 °C. The crystals grew to about 0.4 × 0.4 × 3 mm in 1–2 weeks.

Data collection and phasing. Initial characterization of the crystals and searches for heavy-atom derivatives were performed on room-temperature crystals in an artificial mother liquor containing 2.8 M ammonium sulphate, 100 mM MES pH 6.0. However, the crystals proved to be very radiation sensitive at room temperature and all data sets for MIR phasing and refinement were therefore collected on cryo-cooled crystals. Crystals were cryoprotected with 25% glucose, 1.3 M ammonium sulphate, 100 mM MES pH 6.0 and diffracted to 2.5 Å resolution. The crystals were of space group C2 with unit cell dimensions $a = 146.95$ Å, $b = 68.45$ Å, $c = 65.87$ Å, $\alpha = \gamma = 90.0^\circ$, $\beta = 108.95^\circ$. X-ray data were collected on an R-axisII area detector, reduced using Denzo and Scalepack¹⁴ and processed using the CCP4 suite of programs including MLPHARE and DM¹⁵. The position of the IL-1 β molecule in the complex was determined by molecular replacement with X-plor 3.1 from the PDB coordinates pdb2i1b.ent⁶.

Structure refinement. The s-IL1R structure was traced and rebuilt using program O¹⁶. Refinement by conjugant gradient and simulated annealing was performed in X-PLOR 3.1¹⁷ for all reflections with $F > 2\sigma(F)$ from 15.0 to 2.5 Å ($n = 20,723$). All solvent-accessibility calculations were performed in X-PLOR using the method of Lee and Richards¹⁸, using a 1.4 Å radius probe and assuming that the ligand and receptor structures do not change significantly upon binding. Potential hydrogen bonds were determined using the 'Hbonds_all' facility in O. Salt bridges were assigned in X-PLOR by picking all intermolecular oxygen–nitrogen pairs separated by 3.4 Å or less. Secondary structure assignments were made with the YASSPA algorithm in O and pictures were generated using Setor¹⁹. The current structure contains 31 ordered water molecules and a bulk solvent correction (sol density = 0.40, sol rad = 0.25) was used for the glucose cryoprotectant. The R -factor of the current structure is $R = 23.2\%$ with a free R -factor of 33.1%. In the MIR maps, part of the amino terminus of the first Ig-like domain showed only weak density. For this reason residues 1–8 and 30–41 are not modelled, and the 40–54 loop is poorly defined. Fortunately, this region is distal to the IL-1 binding site, and so does not significantly affect the conclusions of the study. The r.m.s. deviations from ideality are 0.012 Å for bond lengths and 1.98° for bond angles. Running

Procheck on the refined structure showed that four residues are in disallowed regions of the Ramachandran plot. Two of these residues (E11 and Q53) are in the poorly defined region of the molecule whereas the other two (L186 and N246) are at the apex of very tight loops.

Received 18 November 1996; accepted 20 January 1997.

1. Dinarello, C. A. Biologic basis for interleukin-1 in disease. *Blood* 87, 2095–2147 (1996).
2. Labriola-Thompkins, E. et al. Identification of the discontinuous binding site in human interleukin 13 for the type I interleukin 1 receptor. *Proc. Natl Acad. Sci. USA* 88, 11182–11186 (1991).
3. Evans, R. J. et al. Mapping receptor binding sites in interleukin (IL)-1 receptor antagonist and IL-1 β by site-directed mutagenesis. *J. Biol. Chem.* 270, 11477–11483 (1995).
4. Sims, J. E. et al. Cloning the interleukin 1 receptor from human T cells. *Proc. Natl Acad. Sci. USA* 86, 8946–8950 (1989).
5. Vigers, G. P. A. et al. X-ray structure of interleukin-1 receptor antagonist at 2.0 Å resolution. *J. Biol. Chem.* 269, 12874–12879 (1994).
6. Bork, P., Holm, L. & Sander, C. The immunoglobulin fold. Structural classification, sequence patterns and common core. *J. Mol. Biol.* 242, 309–320 (1994).
7. Shapiro, L. et al. Structural basis of cell-cell adhesion by cadherins. *Nature* 374, 327–337 (1995).
8. Priestle, J. P., Schaefer, H. P. & Gruetter, M. G. Crystallographic refinement of interleukin 1 beta at 2.0 Å resolution. *Proc. Natl Acad. Sci. USA* 86, 9667–9671 (1989).
9. Walter, M. R. et al. Crystal structure of a complex between interferon- γ and its soluble high-affinity receptor. *Nature* 376, 230–235 (1995).
10. de Vos, A. M., Ultsch, M. & Kossiakoff, A. A. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. *Science* 255, 306–312 (1992).
11. Livnah, O. et al. Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 Å. *Science* 273, 464–471 (1996).
12. Banner, D. W. et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. *Cell* 73, 431–445 (1993).
13. Greenfeder, S. A. et al. Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex. *J. Biol. Chem.* 270, 1357–13765 (1995).
14. Otwinowski, Z. in *Data Collection and Processing* (eds Sawyer, L., Isaacs, N. & Bailey, S.) (SERC Daresbury Laboratory, Warrington, UK, 1993).
15. CCP4: Collaborative Computational Project No 4, Daresbury UK. *Acta Crystallogr. D* 50, 760 (1994).
16. Jones, T. A., Zou, J. Y., Cowan, S. W. & Kjeldgaard, M. Improved methods for binding protein models in electron density maps and the location of errors in these models. *Acta Crystallogr. A* 47, 110–119 (1991).
17. Brunger, A. T., Kuriyan, J. & Karplus, M. Crystallographic R factor refinement by molecular dynamics. *Science* 235, 458–460 (1987).
18. Lee, B. & Richards, F. M. The interpretation of protein structures: estimation of static accessibility. *J. Mol. Biol.* 55, 379–400 (1971).
19. Evans, S. V. SETOR: hardware-lighted three-dimensional solid model representations of macromolecules. *J. Mol. Graphics* 11, 134–138 (1993).

Acknowledgements. We thank T. Osslund, R. Syed, V. Carperos and C. Kundrot for use of data collection equipment. We thank J. Rizzi and T. Kohnu for stimulating discussions.

Correspondence and requests for materials should be sent to B.J.B. (e-mail: barbara.brandhuber@amgen.com). Atomic coordinates have been deposited with the Brookhaven Protein Data Bank, PDB ID code 1ltb.

A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist

Herman Schreuder^{*,†}, Chantal Tardif^{*,†},
Susanne Trump-Kallmeyer^{*}, Adolfo Soffientini[‡],
Edoardo Sarubbi[‡], Ann Akesson[§], Terry Bowlin[§],
Stephen Yanofsky^{||} & Ronald W. Barrett^{||}

^{*} Marion Merrell Dow Research Institute, 67080 Strasbourg Cedex, France

[†] Lepetit Research Centre, 21040 Gerezano, Italy

[§] Hoechst Marion Roussel Inc., Cincinnati, Ohio 45215-6300, USA

^{||} Affymax, Palo Alto, California 94304, USA

Inflammation, regardless of whether it is provoked by infection or by tissue damage, starts with the activation of macrophages which initiate a cascade of inflammatory responses by producing the cytokines interleukin-1 (IL-1) and tumour necrosis factor- α (ref. 1). Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1 α and IL-1 β and the IL-1-receptor antago-

nist IL1RA (ref. 2). IL-1 is the only cytokine for which a naturally occurring antagonist is known. Here we describe the crystal structure at 2.7 Å resolution of the soluble extracellular part of type-I IL1R complexed with IL1RA. The receptor consists of three immunoglobulin-like domains. Domains 1 and 2 are tightly linked, but domain three is completely separate and connected by a flexible linker. Residues of all three domains contact the antagonist and include the five critical IL1RA residues which were identified by site-directed mutagenesis³. A region that is important for biological function in IL-1 β , the 'receptor trigger site', is not in direct contact with the receptor in the IL1RA complex. Modelling studies suggest that this IL-1 β trigger site might induce a movement of domain 3.

A soluble form of the IL-1 receptor, comprising residues 1–311, was expressed in insect cells and purified by affinity chromatography⁴. The soluble receptor was mixed with recombinant IL1RA at a ratio of 1:1 and was crystallized from 30% PEG3350 at pH 7.0–7.5⁴. The structure has been solved by a combination of molecular replacement and heavy-atom derivatives and has been refined at 2.7 Å resolution to an R factor of 21.1% ($R_{\text{free}} = 31.4\%$) with excellent geometry (see Methods and Table 1). A representative sample of the original squashed multiple isomorphous replacement (MIR) electron density map is given in Fig. 1.

The IL1R molecule resembles a question mark which curls round the IL1RA molecule held in its centre (Fig. 2a). The IL1RA consists of a six-stranded β -barrel closed at one side by three β -hairpin loops and is similar to the structure of the free molecule we solved previously⁵. The root-mean-square (r.m.s.) differences in alpha carbon (C_{α}) positions between bound and free IL1RA are 0.7 Å and 0.8 Å, respectively for the two independent IL1RA molecules present in the crystals of the free IL1RA. The largest differences in the antagonist occur in the loop comprising residues 51–54. This loop interacts with the third IL1R domain but is partially disordered in the free antagonist. Upon binding to IL1R, there is a rotation of the side chain of Glu 52 away from the receptor, a rotation of the side chain of His 54 towards the receptor, and a change in conformation from *cis* to *trans* for Pro 53. Other differences in atomic position greater than 5.0 Å involve solvent-exposed, flexible side chains, namely those of Lys 64, Glu 75, Arg 77, Lys 93, Lys 96, Asp 138, Glu 139 and Lys 145.

As predicted⁶, the folding of the three IL1R domains, consisting of a sandwich of two β -sheets, resembles the folding of immunoglobulin domains. The topology of domains 1 and 2 (residues 1–94 and 106–198) is distantly related to the telokin I-set⁷ topology, although it diverges significantly from the canonical I-set structures. A β -bulge is present between residues 8 and 11 in strand a of domain 1. The β -sheets in domains 1 and 2 are very short, with strand lengths of only 3–4 residues. Strands g and f in domain 2 are long and have extensive contacts with domain 1. Residues involved are Glu 18, Gln 50, His 55 and Val 64 of domain 1, and Tyr 182, Leu 183, Tyr 187, Pro 188 and Thr 190 of domain 2. Domains 1 and 2 are linked through a well-defined β -turn between Pro 98 and Asn 99 which lies on top of the α gfc' sheet (Fig. 2b). Domains 2 and 3 are connected through an extended, flexible linker.

The electron density maps clearly indicated four carbohydrate-binding sites at Asn 173, 213, 229 and 243. The electron density quickly disappears after the first N-acetylglucosamine unit, indicating that most sugar units are disordered. The first attachment site, Asn 173, is at the surface of the second domain and its sugar chain is facing the solvent. The other three attachment sites (Asn 213, 229 and 243) are at the surface of domain 3, and in the natural situation their sugar chains will be close to the cell membrane. Interactions of these sugar chains with the membrane could help to stabilize the orientation of the IL1R with respect to the membrane.

Alignment of the sequence of the extracellular part of the type-I IL1R with homologous proteins (Fig. 3) reveals a number of conserved sequence motifs: the conserved disulphide link and

[†] Present addresses: Hoechst AG, Building Q865A, 65926 Frankfurt, Germany (H.S.); Synthelabo Biomoléculaire, 67080 Strasbourg Cedex, France (C.T.); Parke Davis Pharmaceutical Research, Ann Arbor, MI 48105, USA (S.T.-K.); Biochem Therapeutics, Laval, Quebec H7V4A7, Canada (T.B.).

Procheck on the refined structure showed that four residues are in disallowed regions of the Ramachandran plot. Two of these residues (E11 and Q53) are in the poorly defined region of the molecule whereas the other two (L186 and N245) are at the apex of very tight loops.

Received 18 November 1996; accepted 20 January 1997.

1. Dinarello, C. A. Biologic basis for interleukin-1 in disease. *Blood* 87, 2095–2147 (1996).
2. Labriola-Thompkins, E. *et al.* Identification of the discontinuous binding site in human interleukin 1 β for the type I interleukin 1 receptor. *Proc. Natl Acad. Sci. USA* 88, 11182–11186 (1991).
3. Evans, R. J. *et al.* Mapping receptor binding sites in interleukin (IL)-1 receptor antagonist and IL-1 β by site-directed mutagenesis. *J. Biol. Chem.* 270, 11477–11483 (1995).
4. Sins, J. E. *et al.* Cloning the interleukin 1 receptor from human T cells. *Proc. Natl Acad. Sci. USA* 86, 8946–8950 (1989).
5. Vigers, G. P. A. *et al.* X-ray structure of interleukin-1 receptor antagonist at 2.0 Å resolution. *J. Biol. Chem.* 269, 12874–12879 (1994).
6. Burk, P., Holm, L. & Sander, C. The immunoglobulin fold. Structural classification, sequence patterns and common core. *J. Mol. Biol.* 242, 309–320 (1994).
7. Shapiro, L. *et al.* Structural basis of cell-cell adhesion by cadherins. *Nature* 374, 327–337 (1995).
8. Priestle, J. P., Schaefer, H. P. & Gruetter, M. G. Crystallographic refinement of interleukin 1 beta at 2.0 Å resolution. *Proc. Natl Acad. Sci. USA* 86, 9667–9671 (1989).
9. Walter, M. R. *et al.* Crystal structure of a complex between interferon- γ and its soluble high-affinity receptor. *Nature* 376, 230–235 (1995).
10. de Vos, A. M., Ultsch, M. & Kossiakoff, A. A. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. *Science* 255, 306–312 (1992).
11. Livnah, O. *et al.* Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 Å. *Science* 273, 464–471 (1996).
12. Branner, D. W. *et al.* Crystal structure of the soluble human 55 kD TNF receptor-human TNF beta complex: implications for TNF receptor activation. *Cell* 73, 431–445 (1993).
13. Greenfeder, S. A. *et al.* Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex. *J. Biol. Chem.* 270, 1357–13765 (1995).
14. Orwinowski, Z. in *Data Collection and Processing* (eds Sawyer, L., Isaacs, N. & Bailey, S.) (SERC Daresbury Laboratory, Warrington, UK, 1993).
15. CCP4: Collaborative Computational Project No 4, Daresbury UK. *Acta Crystallogr. D* 50, 760 (1994).
16. Jones, T. A., Zou, J. Y., Cowan, S. W. & Kjeldgaard, M. Improved methods for binding protein models in electron density maps and the location of errors in these models. *Acta Crystallogr. A* 47, 110–119 (1991).
17. Brunger, A. T., Kuriyan, J. & Karplus, M. Crystallographic R factor refinement by molecular dynamics. *Science* 235, 458–460 (1987).
18. Lee, B. & Richards, F. M. The interpretation of protein structures: estimation of static accessibility. *J. Mol. Biol.* 55, 379–400 (1971).
19. Evans, S. V. SETOR: hardware-lighted three-dimensional solid model representations of macromolecules. *J. Mol. Graphics* 11, 134–138 (1993).

Acknowledgements. We thank T. Osslund, R. Syed, V. Carperos and C. Kundrot for use of data collection equipment. We thank J. Rizzi and T. Kohno for stimulating discussions.

Correspondence and requests for materials should be sent to B.J.B. (e-mail: barbara.brandhuber@amgen.com). Atomic coordinates have been deposited with the Brookhaven Protein Data Bank. PDB ID code 1ib.

A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist

Herman Schreuder[†], Chantal Tardif[†],
Susanne Trump-Kallmeyer[†], Adolfo Soffientini[‡],
Edoardo Sarubbi[‡], Ann Akeson[§], Terry Bowlin[§],
Stephen Yanofsky^{||} & Ronald W. Barrett^{||}

[†] Marion Merrell Dow Research Institute, 67080 Strasbourg Cedex, France

[‡] Lepetit Research Centre, 21040 Gerezano, Italy

[§] Hoechst Marion Roussel Inc., Cincinnati, Ohio 45215-6300, USA

^{||} Affymax, Palo Alto, California 94304, USA

Inflammation, regardless of whether it is provoked by infection or by tissue damage, starts with the activation of macrophages which initiate a cascade of inflammatory responses by producing the cytokines interleukin-1 (IL-1) and tumour necrosis factor- α (ref. 1). Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1 α and IL-1 β and the IL-1-receptor antago-

nist IL1RA (ref. 2). IL-1 is the only cytokine for which a naturally occurring antagonist is known. Here we describe the crystal structure at 2.7 Å resolution of the soluble extracellular part of type-I IL1R complexed with IL1RA. The receptor consists of three immunoglobulin-like domains. Domains 1 and 2 are tightly linked, but domain three is completely separate and connected by a flexible linker. Residues of all three domains contact the antagonist and include the five critical IL1RA residues which were identified by site-directed mutagenesis³. A region that is important for biological function in IL-1 β , the 'receptor trigger site', is not in direct contact with the receptor in the IL1RA complex. Modelling studies suggest that this IL-1 β trigger site might induce a movement of domain 3.

A soluble form of the IL-1 receptor, comprising residues 1–311, was expressed in insect cells and purified by affinity chromatography⁴. The soluble receptor was mixed with recombinant IL1RA at a ratio of 1:1 and was crystallized from 30% PEG3350 at pH 7.0–7.5⁴. The structure has been solved by a combination of molecular replacement and heavy-atom derivatives and has been refined at 2.7 Å resolution to an R factor of 21.1% ($R_{\text{free}} = 31.4\%$) with excellent geometry (see Methods and Table 1). A representative sample of the original squashed multiple isomorphous replacement (MIR) electron density map is given in Fig. 1.

The IL1R molecule resembles a question mark which curls round the IL1RA molecule held in its centre (Fig. 2a). The IL1RA consists of a six-stranded β -barrel closed at one side by three β -hairpin loops and is similar to the structure of the free molecule we solved previously⁵. The root-mean-square (r.m.s.) differences in alpha carbon (C α) positions between bound and free IL1RA are 0.7 Å and 0.8 Å, respectively for the two independent IL1RA molecules present in the crystals of the free IL1RA. The largest differences in the antagonist occur in the loop comprising residues 51–54. This loop interacts with the third IL1R domain but is partially disordered in the free antagonist. Upon binding to IL1R, there is a rotation of the side chain of Glu 52 away from the receptor, a rotation of the side chain of His 54 towards the receptor, and a change in conformation from *cis* to *trans* for Pro 53. Other differences in atomic position greater than 5.0 Å involve solvent-exposed, flexible side chains, namely those of Lys 64, Glu 75, Arg 77, Lys 93, Lys 96, Asp 138, Glu 139 and Lys 145.

As predicted⁶, the folding of the three IL1R domains, consisting of a sandwich of two β -sheets, resembles the folding of immunoglobulin domains. The topology of domains 1 and 2 (residues 1–94 and 106–198) is distantly related to the telokin I-set⁷ topology, although it diverges significantly from the canonical I-set structures. A β -bulge is present between residues 8 and 11 in strand a of domain 1. The β -sheets in domains 1 and 2 are very short, with strand lengths of only 3–4 residues. Strands g and f in domain 2 are long and have extensive contacts with domain 1. Residues involved are Glu 18, Gln 50, His 55 and Val 64 of domain 1, and Tyr 182, Leu 183, Tyr 187, Pro 188 and Thr 190 of domain 2. Domains 1 and 2 are linked through a well-defined β -turn between Pro 98 and Asn 99 which lies on top of the agfcc' sheet (Fig. 2b). Domains 2 and 3 are connected through an extended, flexible linker.

The electron density maps clearly indicated four carbohydrate-binding sites at Asn 173, 213, 229 and 243. The electron density quickly disappears after the first N-acetylglucosamine unit, indicating that most sugar units are disordered. The first attachment site, Asn 173, is at the surface of the second domain and its sugar chain is facing the solvent. The other three attachment sites (Asn 213, 229 and 243) are at the surface of domain 3, and in the natural situation their sugar chains will be close to the cell membrane. Interactions of these sugar chains with the membrane could help to stabilize the orientation of the IL1R with respect to the membrane.

Alignment of the sequence of the extracellular part of the type-I IL1R with homologous proteins (Fig. 3) reveals a number of conserved sequence motifs: the conserved disulphide link and

[†] Present addresses: Hoechst AG, Building G865A, 65926 Frankfurt, Germany (H.S.); Synthelabo Bio-moléculaire, 67080 Strasbourg Cedex, France (C.T.); Parke Davis Pharmaceutical Research, Ann Arbor, MI 48105, USA (S.T.-K.); Biochem Therapeutics, Laval, Quebec H7V4A7, Canada (T.B.).

tryptophan, present in the core of many immunoglobulin domains, are absolutely conserved with the exception of IL1R-related protein (IL1RR). A motif that appears to be specific for the IL1R family domains 1 and 2 is a proline immediately after the first cysteine of the conserved core disulphide link. This proline disrupts strand b and is responsible for the very short β sheets observed in domains 1 and 2 of the IL1R. The presence of Asp 20 and Arg 22 on strand b1 at positions usually occupied by highly conserved hydrophobic residues is unusual. The two residues form, together with Ser 14, a hydrophilic cluster in what would otherwise be the hydrophobic core. Almost perfectly conserved is a DxGxYxC motif at the beginning of strands f1 and f2. This motif indicates the presence of a D4 tyrosine corner and is found in many immunoglobulin variable domains⁸. The cysteine of the motif (76 and 176 in IL1R) is part of the core disulphide link. The hydroxyl of the tyrosine makes

a hydrogen bond with the carbonyl oxygen of residue $n - 4$, usually Asp. In domain 1, this Asp makes a salt link with a conserved Arg at the beginning of strand d. The conserved Gly residue in the motif allows the main chain to curve around the tyrosine side chain. Although a D4 tyrosine corner is not present in IL1R domain 3 (the Tyr has been replaced by a Phe and there is a one-residue insertion), the overall conformation of the main chain is similar. Glu 18, at the beginning of strand b1, and Thr 190, halfway along strand g2, make a hydrogen bond in IL1R. These residues are conserved in all sequences, except FGR4, suggesting that the hydrogen bond between them is conserved as well. This would mean that the orientation of domain 1 with respect to domain 2 is similar in these proteins. We conclude from the presence of these common sequence motifs that the proteins listed in Fig. 3 are all similarly folded.




Figure 1 Stereo view of the squashed MIR map contoured at 1σ . Shown is the receptor-antagonist interface in the region around Trp 16 of the antagonist. The refined model of the IL1RA is shown in yellow; IL1R is in green.

Table 1 Crystallographic data

Data collection and phasing statistics				Hg(CN) ₂ + K ₂ PtCl ₆
Data set	Native	Hg(CN) ₂	K ₂ PtCl ₆	
Measured reflections	73,407	71,530	66,081	43,056
Unique reflections	15,631	15,725	14,086	10,835
Resolution (Å)	2.7	2.7	2.8	3.0
Completeness (%)	97.2	98.2	98.5	92.4
$R_{\text{merge}}(\%)^*$	6.0	6.0	6.8	7.5
$R_{\text{iso}}(\%)^\dagger$		22.3	14.8	39.7
Binding sites		1	2	3
Phasing power‡		1.29	0.91	0.68
R_{cutoff}^\S		0.58	0.63	0.69
Mean figure of merit	0.47			
Refinement statistics				
Number of protein atoms		3,638		
Number of sugar atoms (NAG)		56		
Number of water molecules added		86		
Resolution range		8.0–2.7 Å		
Data cutoff		None		
R factor (number of reflections)		21.1% (13,487)		
R_{free} (number of reflections)		31.4% (1,525)		
R_{total} (number of reflections)		22.2% (15,012)		
Average temperature factor		45.2 Å ²		
R.m.s. deviations with respect to ideal (target) values				
Bond lengths		0.004 Å		
Bond angles		1.2°		
Dihedrals		26.5°		
Impropers		1.0°		

NAG, *N*-acetylglucosamine.

* $R_{\text{merge}} = \sum_i \sum_j |I_{hkl,i} - I_{hkl,j}| / \sum_i \sum_j I_{hkl,i}$.

† $R_{\text{iso}} = \sum_i |F_{\text{obs}} - F_{\text{calc}}| / \sum_i |F_{\text{obs}}|$.

‡ Phasing power = $\sum_i |F_{\text{obs}}| / \sum_i |F_{\text{calc}}|$ (lack of closure).

§ $R_{\text{cutoff}} = (\text{lack of closure}) / (\text{isomorphous differences})$ for centric reflections, as calculated by HEAVY².

letters to nature

A large area of $1,774 \text{ \AA}^2$ of the IL1RA surface and $1,767 \text{ \AA}^2$ of the receptor surface (calculated by using DSSP⁹) gets buried upon receptor binding (Fig. 4). This area corresponds to about 20% of the total surface of IL1RA and may explain the tight binding ($\sim 10^{-9} \text{ M}$)⁶ of the antagonist to the receptor.

The IL1RA molecule interacts with all three receptor domains. Leu 25, Arg 26, Asn 27, Glu 29, Leu 42 and Pro 130 contact strand a and loop bc in the N-terminal half of receptor domain 1. The loop comprising residues 34–39, which is fully exposed in the crystal structure of free IL1RA⁵, fits in the cleft between domains 1 and 2. Arg 14, Trp 16, Val 18, Asn 19, Gln 20, Ala 127, Asp 128, Tyr 147 and Gln 149 contact strands of both sheets of the β -sandwich of domain 2. Finally, Ser 8, Lys 9, Pro 50, Ile 51, Pro 53, His 54, Leu 56, Glu 150 and Asp 151 contact loops bc and fg at the top of domain 3 (Fig. 2).

The interactions between the IL1R and the antagonist are mainly polar in character. We observe only three hydrophobic contacts (Table 2). Surprisingly, despite the many charged residues on the IL1R and the antagonist, we find only two direct and one indirect

Table 2 Selected interactions ($d \leq 3.5 \text{ \AA}$) between the IL1R and IL1RA

Side-chain-side-chain interactions		Interactions involving the main chain	
Receptor	Antagonist	Receptor	Antagonist
Salt links		Receptor side chain to antagonist main chain	
Glu 8	Arg 26	Lys 9	Leu 25
Arg 268	Glu 150	Glu 126	Ala 127
Hydrogen bonds		Tyr 124	Tyr 34
Tyr 124 OH	Asp 128 o62	Arg 160	Val 18
Ser 235 O γ	Gln 11 O ϵ 1	Receptor main chain antagonist side chain	
Hydrophobic contacts		Ile 11	Asn 39*
Ile 10	Leu 42	Val 13	Gln 36*
Leu 198	Trp 16	Ala 106	Gln 36
Pro 113	Tyr 147	Lys 111	Trp 16
		Lys 111	Gln 20*
		Gly 119	Gln 20
		Receptor main chain to antagonist main chain	
		Ile 107	Gly 37
		Asn 296	Pro 53
		Thr 297	His 54

* These residues make two hydrogen bonds: one from the side-chain amide to the main-chain carbonyl, and one from the side-chain carbonyl to the main-chain amide.




Figure 2 Structure of the IL1R:IL1RA complex. **a**, Ribbon diagram²⁹. Shown are two views of the complex, 90° apart. The antagonist is yellow, the receptor domains 1, 2 and 3 are red, green and blue, respectively. In the full-length receptor, the C terminus of domain 3 (blue) is connected to the membrane-spanning domain. This means that in the natural situation, the membrane will be near the bottom of the figure. **b**, Topology of the IL1R. The secondary structure elements have been determined by DSSP⁹. The lengths of the strands are proportional to the number of amino acids they contain. Receptor residues that are buried by the ligand are indicated by a star.

IL1R_humandkckere	aKII LVSSAN	VRP LN	PNEHK----gci T	RDSkt pva	teqaa-----	52	
IL1S_human	(il qpaahtg	aarscri rgr	hYKREFRLEG	SPVALR OV	PYWLW----	svapri ni T	HKMDSartvp	geast-----	71
IL1RR_humansac	srPHI TVVEG	SPFYLKHCSC	SLAHE----l et t S	XSSGaqebv	alnpress---	55	
AcP_murinesha	sercddwgd	tMRQI QVFED	EPARI KLF	EHFLKyayl	ahsagi t i	WTRQdrdl e	epi nrl pen	73
ST2_human	SKQSWGLEN	BALI VR	ERQ	YSOTaksl p	tqera-----	43	
FGR4_humanseevol	epcl apsl eq	qEQELTVALG	QEVRLC GRA	ERGG-----H	KEGSrlapa	g-----	53

IL1R_humanHONKEKRW	EVPAKVERST	HYV VV	ysci riklsak	iven-----	EPNL	RYNAQAI FKQ	110
IL1S_humanMAQDGAH	LLALQELST	TVVTTT	ycdkmsleir	vi-----	ENTD	AFLPFI SYPO	127
IL1RR_humanALHDCVDE	FWVELNST	SVFFOM	qkwlavirr	-----	NKHS	ETERQVTSK	109
AcP_murineSKEKDVW	FRITLLNST	NITML	ysakvalpl e	vv-----	OKDS	ENSAMRFPV	129
ST2_humanVFASGOLIK	ELDAEVA	INTA V	lartgyaovt	lyk-----	KQSD	NVPOYLMYS	100
FGR4_humanVRGWRGR	IASFLPE	RLA LA	ivi qnlitit	gdsitaaedd	edpkabrdpa	arhsypQQAP	YWTHPQRMEK	133

IL1R_human	KLpva---gd	gGLV	ymel	lknemELPK	LOVYD	KPE	LLOMI HFSgv	kdrilvmava	e---KHRNHASYTYL	183
IL1S_human	l l l s---ts	gVLV	adi se	l l r d- KTOVK	LOVYD	SSL	DKOMEKFLav	rgtthl lvhd	val---EALYNLTFaHE	201
IL1RR_human	l Vavk---kl	l QI T	Easyy	q---TLVNS	TSLY	AKKE	LLENMKNPI	kkascl---EDCYSVHFLHMH	173
AcP_murine	HKayl---ehg	hkl T	nvvg	yipa-SVKPS	VTLV	GATEI	VDFHNVLPag	malstfllplvSNMNVVTYPEN	202
ST2_human	TVsgs---ekn	skl Y	ldi	y---NMTAP	LEF	HAQAI	QGSRYRAHks	flvl dnmvEDADKFI HNEN	168
FGR4_human	KLhavpagnl	vKFR	aaqNPTPT	IRL	OGQAF	HGENRI GGI r	lrhghwalvm	eevvpSQRITLVENAVG	207

IL1R_humanKONPI	RV	atititlenkp	trpvlvspan	etme---VOL	SQI OI	NVT	GCI---	adi	AY	KWNqavl	daddpvt ged	257
IL1S_humanGOONI	RSI	alrikkkke	tlqvllaplk	l l s---ASL	SRLTI P	KVF	LGTGTPLTTM	LW	TANDTHI	asaypggrvt	278	
IL1RR_humanKLI	NI	KT	nitivedran	ahva---VEL	KNVREN	SAL	LNa---	edv	IY	MFGaeng	sdplvhaek	247
AcP_murineRL	HL	RTV	tykvvgapkd	drvvyeKEP	EELVI P	KVY	FSf l	dashne	VM	TI Dgkpk	ddvlvdi lla	282
ST2_humanAN	SV	ATr	sttkvdeggi	alipvlgapa	qneikveEI	KNANET	SAC	FGKGTQFLAA	VL	OLNGTKI	tdipepirlq	248
FGR4_human	SI	RL	NYLLOv	leraphrpil	qagipantl-AVV	SOVELL	KVY	SOa---qphl q	---	khilvin	gsal gadgip	276

IL1R_humanyysvenpauk	rratititven	ESSEI ESFRYK	HPIT	FAKKE	HB	daayl q	lypvtatqk-	316
IL1S_humanegprqaysea	nanyilevpt	FDPVTREDEH	MOX	VVH	LSI	qlitrlty	keastflaw-	337
IL1RR_humanarlampeg--	-kwhaskvER	ENI GESNUN	VLN	TVAST	GS	dtksll	vrkadmadip	304
AcP_murineeavsyast--	edetrql LS	KKVTPEDER	RMV	HARR	Kbae	qaaky	kqkvppryl	340
ST2_humaneagqqsifsn	glacldawLR	EADVKEEDEL	LOD	LAL	HO	rrhtvr	erkapskecl	308
FGR4_humanyvqrlkfa--	dlnasseveVL	YLRNVSAAEDA	GENT	LAGS	IS	syqsaw	tlvpeadptw	334

Figure 3 Sequence alignment of the extracellular portion of the IL1R with the extracellular portions of 5 homologous proteins. IL1R, type-I IL-1 receptor; IL1S, type-II IL-1 receptor; IL1RR, IL-1-receptor-related protein; AcP, IL-1-receptor accessory protein; ST2, ST2 protein; FGR4, fibroblast growth factor receptor 4. The cysteines and tryptophans that are conserved in most immunoglobulin folds are indicated in dark blue. Also highlighted are the prolines immediately following

conserved cysteines, which appear to be conserved in the particular immunoglobulin fold of IL-1 domains 1 and 2. Highlighted in green are 5 conserved cysteine pairs which, based on the IL1R structure, are likely to form disulphide bonds. Other highly conserved residues are indicated in blue. Conserved glutamic acids and threonines, which are probably involved in a hydrogen bond between domains 1 and 2, are indicated in red.




Figure 4 Space-filling model of bound IL1RA. Residues shown by mutagenesis to be important for receptor interaction³ are in red, other residues that are buried by the receptor are in blue, and those that do not interact with the receptor are in yellow. The five residues defined by site-directed mutagenesis are right in the centre of the area that is buried by the receptor in the crystal structure. However, the contact area defined by the mutagenesis studies is only 29% of the area defined by the crystal structure, suggesting that many of the contacting residues contribute less significantly to the overall binding energy.



Figure 5 Comparison of the IL1R (left) and HGHR (right) complexes. IL1RA is shown in yellow, IL1R in green, HGH in red and the two HGHR molecules in blue and magenta. The two receptors use opposite faces of the immunoglobulin domains to bind their ligands.

letters to nature

salt link (Lys 11R and Glu 43A are linked through a water molecule). Some oppositely charged side chains (Lys 129R–Glu 126A, Lys 295R–Glu 52A, Lys 295R–Glu 90A) are less than about 8 Å apart, but do not seem to make any direct interactions. It may be that for these residue pairs, the gain in electrostatic energy is offset by a loss of entropy. This idea is supported by a mutagenesis study that shows that one of the salt links in the crystal structure of human growth hormone complexed to its receptor¹⁰ contributes little, if anything, to the overall binding energy, an effect the authors ascribe to entropy loss.

We observe only two side-chain–side-chain hydrogen bonds between the receptor and the antagonist. Most of the hydrogen bonds between antagonist and receptor involve main-chain carbonyl or nitrogen atoms (Table 2). Of special interest are the double hydrogen bonds made by Gln 20, Gln 36 and Asn 39 of the antagonist with the backbone of the receptor, which suggests that these residues may contribute significantly to the overall binding. The potential advantages of using main-chain atoms for receptor–ligand interactions are twofold: the main chain is usually more rigid than the side chains so that the entropy loss for the main chain will be less than for side chains; and interactions involving main-chain atoms depend less on the sequence and more on the overall folding than interactions between side chains, which may explain how the IL1R is able to bind its three natural ligands, IL-1 α , IL-1 β and IL1RA with high affinity, despite the low sequence identity (20–25%) between them.

The crystal structure of the receptor complex fully explains the published mutagenesis studies. IL1RA residues Trp 16, Gln 20, Tyr 34, Gln 36 and Tyr 147, identified as critical for antagonist binding³, are all in direct contact with the receptor (Table 2; Fig. 4). The same residues (Tyr, Trp, Gln) are present in the YWQPWA consensus sequence, identified by affinity screening using phage

display peptide libraries¹¹. The indole side chain of Trp 16 is completely buried by the receptor and makes a hydrogen bond with the carbonyl oxygen of Lys 111. The side chain of Gln 20 makes two hydrogen bonds with the receptor backbone. The side chain of Tyr 34 makes no direct contacts of less than 3.5 Å with the receptor. It does face a hydrophobic region on the receptor surface, consisting of the side chains of Phe 108, Val 121, Pro 123 and Tyr 124. The side chain of Tyr 34 is tightly fixed in position by a hydrogen bond with the carbonyl oxygen of Asn 19 and its carbonyl oxygen makes a hydrogen bond with the hydroxyl group of Tyr 124. The Gln 36 side chain is found in a pocket between receptor domains 1 and 2 and makes three hydrogen bonds with the receptor backbone. These hydrogen bonds and the restricted pocket clearly explain the large loss of binding affinity associated with the Gln 36 \rightarrow Phe mutation. Finally, the hydroxyl of the critical Tyr 147 binds to a network of two fixed water molecules on top of loop bc of receptor domain 2.

The binding of IL1RA in the IL1R complex is fundamentally different from the binding of ligands in the cytokine–receptor complexes whose three-dimensional structures are known. In the tumour necrosis factor- β (TNF- β) complex¹², three elongated receptor molecules are bound to the ligand and the receptor domains do not possess an immunoglobulin fold. In the receptor complexes with human growth hormone (HGHR¹³), interferon- γ (IFN γ R¹⁴) and erythropoietin peptide (EPOR¹⁵), the ligand binds to the outside of the elbow between two immunoglobulin-like domains of the fibronectin type and is sandwiched between two receptor molecules (Fig. 5). In the IL1RA complex, the receptor has three immunoglobulin-like domains and the ligand binds to the inside of the elbow formed by domains 1 and 2.

Another way in which the IL1R differs from HGHR, IFN γ R and many other proteins with immunoglobulin-like domains is in the interactions between its domains. Most immunoglobulin-like




Figure 6 Model obtained after superimposing IL-1 β onto IL1RA in the complex. IL-1 β is indicated in magenta and the receptor in green. After this superposition, a region of positively charged residues (Arg 4, Lys 92, Lys 93 and Lys 94) in IL-1 β is at a distance of ~ 15 Å from a region of negatively charged residues (Asp 248, Glu 249, Asp 251, Glu 256 and Asp 257) in domain 3 of IL1R but do not directly interact with them. Modelling studies (not shown) suggest that upon movement of IL1R domain 3, these two regions interact directly. A definitive answer must come from the crystal structure of the IL1R–IL1 β complex.




Figure 7 Solvent-accessible surface of the IL1R, coloured according to the electrostatic potential using GRASP¹⁶. The contours run from $-5K_B T$ (red) to $+5K_B T$ (blue), where K_B is the Boltzmann constant and T the absolute temperature. The IL1RA molecule is peeled off and rotated by 90° to show the receptor-binding region.

domains are connected by relatively short linkers which allow flexibility while maintaining contact between the domains. Domains 1 and 2 of IL1R are close together and have tight and extensive contacts. The upper halves of strands f2 and g2 (Fig. 2) in particular have more contacts with domain 1 than with domain 2 to which they belong. The centres of mass of domains 1 and 2 are ~ 8 Å closer in IL1R than they are in HGHR. Judging from the crystal structure, it seems unlikely that domains 1 and 2 are able to move with respect to each other, suggesting that domains 1 and 2 could behave as a single module. The connection between domains 2 and 3, on the other hand, is a long and flexible linker with no direct contacts between the domains. We would therefore expect that domain 3 is able to move with respect to domains 1 and 2 when no ligand is present.

An IL-1-receptor-like protein, the IL1R accessory protein, may be involved in the IL-1 response¹⁶. Association of this accessory protein with the complex of the IL1R with the agonists IL-1 α or IL-1 β is believed to trigger the receptor response. The accessory protein might need binding sites both on the IL1R and on the agonists IL-1 α or IL-1 β , or alternatively, the agonists may induce a conformational change in the receptor which allows binding of the accessory protein.

We investigated these possibilities by constructing a preliminary model of IL-1 β bound to the receptor, in which the structure of IL-1 β ¹⁷ was superimposed onto IL1RA in the complex by means of a procedure described before⁵. We compared this model of the complex with the extensive mutagenesis data available for IL-1 β ⁵. Some IL-1 β residues that are important for binding (Arg 11, His 30, Asn 108 and Glu 128) are all close to the receptor after superimposition and face receptor domains 1 and 2, indicating that similar regions on the surface of IL-1 β and IL1RA may interact with receptor domains 1 and 2.

The situation is quite different for residues facing domain 3. Whereas Lys 92 and Lys 94 are part of the proposed receptor trigger site², after superimposition they are facing the solvent and do not interact with the receptor. They are part of a highly positively charged region on IL-1 β involving Arg 4, Lys 92, Lys 93 and Lys 94, about 15 Å away from a region rich in negative charged on the receptor, involving Asp 248, Glu 249, Asp 251, Glu 256 and Asp 257 (Fig. 6). Electrostatic calculations (Fig. 7) indicate that this negative patch, together with a negative patch on top of domain 1, are the strongest features on the relatively featureless electrostatic surface. The close complementarity of the positive and negative sites suggests that they might interact directly with each other. A rotation of domain 3 of $\sim 20^\circ$ would bring the two sites together. The flexible linker between domains 2 and 3 allows such a rotation, which would make the conformation of the IL1 β -receptor complex more closed than that of the IL1RA-receptor complex, inducing binding of the accessory protein and hence activation of the receptor. Without a crystal structure of the IL1 β -receptor complex, however, we cannot exclude the possibility that the accessory protein will simply bind between the two charged regions.

To test the importance of domain 3 for agonist and antagonist binding, we prepared a truncated receptor consisting only of domains 1 and 2. This truncated receptor binds IL-1 α and IL-1 β with low affinity (dissociation constant (K_d) values of 7 μ M and >10 μ M, respectively) whereas it binds IL1RA with high affinity (K_d 28 nM). This shows that agonists, but not antagonists, need domain 3 for high-affinity binding and suggests that domain 3 strongly interacts with IL-1 agonists.

Residue 145 (Asp in IL-1 β , Lys in IL1RA), which is crucial in determining agonist or antagonist activity¹⁸, does not interact directly with the receptor, either in the IL1RA complex or in our model of the IL-1 β complex (Fig. 6), suggesting that this residue might be important for interaction with the accessory protein.

The structure presented here illustrates in detail a new binding

mode for cytokine receptors and provides insight into the possible differences between agonist and antagonist interaction. □

Methods

Equipment and crystals. The IL1R-antagonist complex was crystallized as described⁴. Native and heavy-atom data were recorded with a Siemens X1000 area detector, mounted on a Siemens rotating-anode generator equipped with a copper anode and graphite monochromator, operating at 50 kV and 90 mA. The crystals had dimensions of $\sim 0.2 \times 0.3 \times 0.5$ mm³ and one crystal was used per data set. Data were processed using XDS software¹⁹. The space group was $P2_12_12_1$, with $a = 47.2$ Å, $b = 84.6$ Å and $c = 140.2$ Å.

Structure solution. The structure was solved with a combination of molecular replacement and heavy-atom derivatives. For molecular replacement, we used the AMoRe package²⁰ and data between 15.0 and 4.0 Å. The structure of the free IL1RA as solved by us⁵ gave clear solution with a correlation of 25.8% (R factor = 51.3%). We tried structures of various protein domains with immunoglobulin folds but most of them did not produce any clear signal, probably because these models were too different from the receptor domains and because one receptor domain represents only a small fraction of the total contents of the asymmetric unit of the crystals. A truncated model of the first CD4 domain²¹, however, gave a correlation of 29.2% in combination with the IL1RA model (R factor 50.3%). The maps, based on this partial model, were not readily interpretable and it was therefore decided to search for heavy-atom derivatives. We obtained two independent heavy-atom derivatives and one double derivative. Scaling of heavy-atom derivative data, calculation of Pattersons and refinement of heavy-atom parameters were done by using programs from the CCP4 suite²². Heavy-atom positions were located in difference Patterson maps and the parameters were refined with HEAVY²³. Phases were calculated with MLPHARE²⁴. Cross-difference Fouriers were used to define a common origin and to confirm the sites. Difference fouriers using phases from the partial model, obtained by molecular replacement, did not reproduce the sites, indicating that the model phases were rather poor. This is most probably caused by the large fraction of the diffracting matter (two receptor domains), which is missing in the partial model. However, phased translation functions²⁵ using phases from the partial model and single isomorphous replacement (SIR) phases calculated with the Hg(CN)₂ and K₂PtCl₄ derivatives, defined a common origin and indicated the correct hand for the heavy-atom solution. The MIR map, calculated with three derivatives, was improved by solvent flattening and histogram matching using SQUASH²⁶. Map interpretation and model building were done using the program O²⁷. The model of IL1RA needed only minor rebuilding, but the model of the truncated CD4 domain needed major rebuilding to become an IL1R domain; two additional receptor domains had to be built from scratch. The structure was refined by simulated annealing and energy minimization using X-PLOR²⁸. The final model contains residues 7–151 of the IL1RA and residues 1–311 of the IL1R.

Binding studies. Truncated receptors were expressed on the surface of CHO cells and radiolabelled peptides were used for competitive binding¹¹.

Received 4 November 1996; accepted 4 February 1997.

1. Baumann, H. & Gauldie, J. The acute phase response. *Immunol. Today* 15, 74–80 (1994).
2. Dinarello, C. A. The interleukin-1 family: 10 years of discovery. *FASEB J.* 8, 1314–1325 (1994).
3. Evans, R. J. *et al.* Mapping receptor binding sites in interleukin (IL)-1 receptor antagonist and IL-1 β by site-directed mutagenesis. Identification of a single site in IL-1ra and two sites in IL-1 β . *J. Biol. Chem.* 270, 11477–11483 (1995).
4. Schreuder, H. A. *et al.* Crystals of soluble interleukin-1 receptor complexed with its natural antagonist reveal a 1:1 receptor-ligand complex. *FEBS Lett.* 373, 39–40 (1995).
5. Schreuder, H. A. *et al.* Refined crystal structure of the interleukin-1 receptor antagonist. Presence of a disulfide link and a cis proline. *Eur. J. Biochem.* 227, 838–847 (1995).
6. Sims, J. E. *et al.* cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily. *Science* 241, 585–589 (1988).
7. Harpaz, Y. & Chothia, C. Many of the immunoglobulin superfamily domains in cell adhesion molecules and surface receptors belong to a new structural set which is close to that containing variable domains. *J. Mol. Biol.* 238, 528–539 (1994).
8. Hemmingsen, J. M., Gernert, K. M., Richardson, J. S. & Richardson, D. C. The tyrosine corner: A feature of most greek key β -barrel proteins. *Prot. Sci.* 3, 1927–1937 (1994).
9. Kabsch, W. & Sander, C. Dictionary of protein secondary structure: Pattern recognition of hydrogen-bonded and geometrical features. *Biopolymers* 22, 2577–2637 (1983).
10. Clackson, T. & Wells, J. A. A hot spot of binding energy in a hormone-receptor interface. *Science* 267, 383–386 (1995).
11. Yanovsky, S. D. *et al.* High affinity type I interleukin 1 receptor antagonists discovered by screening recombinant peptide libraries. *Proc. Natl Acad. Sci. USA* 93, 7381–7386 (1996).
12. Banner, D. W. *et al.* Crystal structure of the soluble human 55 kD TNF receptor-human TNF β complex: Implications for TNF receptor activation. *Cell* 73, 431–445 (1993).

13. Vos, A. M., Ultsch, M. & Kossiakoff, A. A. Human growth hormone and extracellular domain of its receptor: Crystal structure of the complex. *Science* 255, 306–312 (1992).
14. Walter, M. R. *et al.* Crystal structure of a complex between interferon- γ and its soluble high-affinity receptor. *Nature* 376, 230–235 (1995).
15. Livnah, O. *et al.* Functional mimicry of a protein hormone by a peptide agonist: The EPO receptor complex at 2.8 Å. *Science* 273, 464–471 (1996).
16. Greenfeder, S. A. *et al.* Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex. *J. Biol. Chem.* 270, 13757–13765 (1995).
17. Priestle, J. P., Schür, H.-P. & Grütter, M. G. Crystal structure of the cytokine interleukin-1 β . *EMBO J.* 7, 339–343 (1988).
18. Ju, G. *et al.* Conversion of the interleukin 1 receptor antagonist into an agonist by site-specific mutagenesis. *Proc. Natl Acad. Sci. USA* 88, 2658–2662 (1991).
19. Kabsch, W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. *J. Appl. Crystallogr.* 26, 795–800 (1993).
20. Navaza, J. AMoRe: an automated package for molecular replacement. *Acta Crystallogr. A* 50, 157–163 (1994).
21. Wang, J. *et al.* Atomic structure of a fragment of human CD4 containing two immunoglobulin-like domains. *Nature* 348, 411–418 (1990).
22. Collaborative Computational Project Number 4. The CCP4 suite: Programs for protein crystallography. *Acta Crystallogr. D* 50, 760–763 (1994).
23. Terwilliger, T. C. & Eisenberg, D. Unbiased three-dimensional refinement of heavy-atom parameters by correlation of origin-removed Patterson functions. *Acta Crystallogr. A* 39, 813–817 (1983).
24. Otwinowski, W. Maximum likelihood refinement of heavy atom parameters. In *Isomorphous Replacement and Anomalous Scattering Proc. CCP4 Study Weekend*, 25–26 January 1991 (compiled by Wolf, W., Evans, P. R. & Leslie, A. G. W.) 80–86 (1991).
25. Read, R. J. & Schierbeck, A. J. A phased translation function. *J. Appl. Crystallogr.* 13, 490–495 (1988).
26. Zhang, K. Y. J. SQUASH—combining constraints for macromolecular phase refinement and extension. *Acta Crystallogr. D* 49, 213–222 (1993).
27. Jones, T. A., Zou, J.-Y., Cowan, S. W. & Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models. *Acta Crystallogr. A* 47, 110–119 (1991).
28. Brünger, A. X-PLOR, version 3.1. A system for X-ray crystallography and NMR (Yale University Press, New Haven, Connecticut, 1992).
29. Kraulis, P. MOLSCRIPT: A program to produce both detailed and schematic plots of protein structures. *J. Appl. Crystallogr.* 24, 946–950 (1991).
30. Nicholls, A., Sharp, K. A. & Honig, B. Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons. *Proteins* 11, 281–296 (1991).

Acknowledgements. We thank I. A. Malikyil and T. Pelton for discussion and A. Bateman for advice on the classification of domains 1 and 2.

Correspondence and requests for materials should be addressed to H.A.S. (e-mail: hschreuders@trahmr.hoechst.com). Coordinates will be deposited with the Brookhaven Protein Data Bank and will be released after one year.


ERRATUM

Viable offspring derived from fetal and adult mammalian cells

I. Wilmut, A. E. Schnieke, J. McWhir, A. J. Kind & K. H. S. Campbell

Nature 385, 810–813 (1997).

In this Letter in the 27 February issue, a production error led to the image for part b of Fig. 1 (fetal fibroblasts) being used twice, as parts b and c. The correct image for Fig. 1c (mammary-derived cells) is shown below, and is also on the *Nature* web site and in reprints.



YOURS TO HAVE AND TO HOLD BUT NOT TO COPY


The publication you are reading is protected by copyright law. This means that the publisher could take you and your employer to court and claim heavy legal damages if you make unauthorised infringing photocopies from these pages.

Photocopying copyright material without permission is no different from stealing a magazine from a newsagent, only it doesn't seem like theft.

The Copyright Licensing Agency (CLA) is an organisation which issues licences to bring photocopying within the law. It has designed licensing services to cover all kinds of special needs in business, education, and government.

If you take photocopies from books, magazines and periodicals at work your employer should be licensed with CLA.

Make sure you are protected by a photocopying licence.



The Copyright Licensing Agency Limited
90 Tottenham Court Road, London W1P 0LP
Telephone: 0171 436 5931
Fax: 0171 436 3986